

Cancer Incidence and Mortality in New Jersey 2003-2007

**Cancer Epidemiology Services
Public Health Services Branch
New Jersey Department of Health and Senior Services**



**Chris Christie, Governor
Kim Guadagno, Lt. Governor**



**Poonam Alaigh, MD, MSHCPM, FACP
Commissioner**

You are viewing an archived copy from the New Jersey State Library

Cancer Incidence and Mortality in New Jersey 2003 - 2007

Prepared by:

Xiaoling Niu, MS

Stasia S. Burger, MS, CTR

Karen Pawlish, ScD, MPH

Kevin A. Henry, PhD

Cancer Epidemiology Services

Public Health Services Branch

New Jersey Department of Health and Senior Services

Christina G. Tan, MD, MPH

Assistant Commissioner/State Epidemiologist

Susan Walsh, MD, FACP

Deputy Commissioner

Poonam Alaigh, MD, MSHCPM, FACP

Commissioner

Chris Christie, Governor

Kim Guadagno, Lt. Governor

Cancer Epidemiology Services

New Jersey Department of Health and Senior Services

PO Box 369

Trenton, NJ 08625-0369

(609) 588-3500

<http://nj.gov/health/ces/index.shtml>

March 2010

ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Surveillance Program of the Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

| | |
|---------------------------|----------------------------|
| Pamela Agovino, MPH | Fran Krol, CTR |
| Tara Blando, MPH | Mireille Lemieux, CTR |
| Donna Brown-Horn, CTR | Henry Lewis, MPH |
| Kathleen Diszler, RN, CTR | Helen Martin, CTR |
| Thomas English, CTR | Ilsia Martin, MS |
| Lorraine Fernbach, CTR | Kevin Masterson, CTR |
| Ruthann Filipowicz | Carl C. Monetti |
| Raj Gona, MPH, MA | John Murphy, CTR |
| Maria Halama, MD, CTR | Lisa Paddock, MPH |
| Essam Hanani, MD, CTR | Maithili Patnaik, CTR |
| Denise Hansen | Theresa Pavlovcak, CTR |
| Marilyn Hansen, CTR | Karen Pawlish, MPH, ScD |
| Joan Hess, RN, CTR | Gladys Pyatt-Dickson, CTR |
| Yvette Humphries | Karen Robinson-Fraser, CTR |
| Nicole Jackson | Lisa M. Roche, MPH, PhD |
| Jamal Johnson, CTR | Marcelina Rosario |
| Linda Johnson, CTR | Antonio Savillo, MD, CTR |
| Catherine Karnicky, CTR | Suzanne Schwartz, MS, CTR |
| Harrine Katz, CTR | Celia Troisi, CTR |
| Joan Kay, CTR | Homer Wilcox III, MS |

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN261200544005C ADB No. N01-PC-54405, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement 1 U58/DP000808, and the State of New Jersey.

TABLE OF CONTENTS

| | |
|---------------------------------------|----|
| Introduction..... | 1 |
| Summary..... | 2 |
| Technical Notes..... | 4 |
| New Jersey State Cancer Registry..... | 4 |
| Data Sources and Specifications..... | 6 |
| Data Presentation..... | 9 |
| References..... | 11 |

TABLES

| | | |
|-----------|--|----|
| Table 1. | Age-adjusted Incidence Rates, Males (all races combined)..... | 14 |
| Table 2. | Age-adjusted Incidence Rates, Females (all races combined)..... | 16 |
| Table 3. | Age-adjusted Incidence Rates, White Males..... | 18 |
| Table 4. | Age-adjusted Incidence Rates, White Females..... | 20 |
| Table 5. | Age-adjusted Incidence Rates, Black Males..... | 22 |
| Table 6. | Age-adjusted Incidence Rates, Black Females..... | 24 |
| Table 7. | Age-adjusted Incidence Rates, Hispanic Males and Females (combined years)... | 26 |
| Table 8. | Benign and Borderline Brain Tumor Incidence Rates, 2004-2007..... | 28 |
| Table 9. | Comparative Incidence Rates, New Jersey and U.S., 2002-2006: Males..... | 29 |
| Table 10. | Comparative Incidence Rates, New Jersey and U.S., 2002-2006: Females..... | 29 |
| Table 11. | Age-adjusted Mortality Rates, Males (all races combined)..... | 30 |
| Table 12. | Age-adjusted Mortality Rates, Females (all races combined)..... | 32 |
| Table 13. | Age-adjusted Mortality Rates, White Males..... | 34 |
| Table 14. | Age-adjusted Mortality Rates, White Females..... | 36 |
| Table 15. | Age-adjusted Mortality Rates, Black Males..... | 38 |
| Table 16. | Age-adjusted Mortality Rates, Black Females..... | 40 |
| Table 17. | Age-adjusted Mortality Rates, Hispanic Males and Females (combined years)... | 42 |
| Table 18. | Comparative Mortality Rates, New Jersey and U.S., 2002-2006: Males..... | 44 |
| Table 19. | Comparative Mortality Rates, New Jersey and U.S., 2002-2006: Females..... | 44 |
| Table 20. | Population Denominators..... | 45 |
| Table 21. | Age Distribution of Cancer Incidence Cases..... | 47 |
| Table 22. | Median Age at Cancer Diagnosis..... | 48 |

INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2003-2007, age-adjusted mortality rates and counts for the period 2003-2006 and comparisons of state and national rates for 2002-2006. The New Jersey cancer incidence data for 2007 are considered preliminary. U.S. cancer incidence data and cancer mortality data for 2007 are not yet available.

The primary goal of this report is to provide 2003-2007 cancer data to healthcare planners, researchers and the public. Data are provided statewide for six population subgroups: white men, white women, black men, black women, Hispanic men and Hispanic women. Data are also provided by gender for all races combined.

For each year, the age-adjusted incidence and mortality rates per 100,000 population are shown for 69 categories of cancer and for all sites combined. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. These conventions are standard practice for publication of cancer rates in the United States. According to public law, benign and borderline brain tumors diagnosed on or after January 1, 2004 are required to be reported to cancer registries. The incidence data for 2004-2007 are presented in Table 8.

Additional New Jersey cancer incidence, mortality, survival, and prevalence data are available from the Cancer Epidemiology Services office or on our website, <http://nj.gov/health/ces/index.shtml>, including:

- *Adolescent and Young Adult Cancer in New Jersey-1979-2006*;
- *Childhood Cancer in New Jersey, 1979-2005*;
- *Area Socioeconomic Variations in Cancer Incidence and Stage at Diagnosis in New Jersey, 1996-2002*;
- *Cancer Survival in New Jersey 1979-1999*; and
- *Cancer Prevalence in New Jersey on January 1, 2003*

Our interactive cancer data mapping application provides incidence counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1990-2007 and mortality counts and rates for the years 1990-2006 at <http://www.state.nj.us/health/ces/index.shtml>. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet, <http://cancercontrolplanet.cancer.gov/>
- North American Association of Central Cancer Registries' *Cancer in North America 2002—2006*, <http://www.naaccr.org/cancerinnorthamerica>
- Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics, <http://surveillance.cancer.gov/statistics/>

SUMMARY

NEW JERSEY CANCER INCIDENCE AND MORTALITY DATA, 2003-2007

A total of 47,388 cases of invasive cancer diagnosed in 2007 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), compared to 46,569 reported cases diagnosed in 2006. During the period 2003-2007, a total of 231,824 cases of invasive cancer were diagnosed among New Jersey residents, 50.7 percent among men and 49.3 percent among women, 84.6 percent among whites and 10.7 percent among blacks.

The top primary cancers with the highest age-adjusted incidence rates in 2003-2007 in New Jersey were prostate, lung, colon and rectum, urinary bladder, melanoma of the skin, non-Hodgkin lymphoma, and kidney and renal pelvis for men; and breast, lung, colon and rectum, endometrial (corpus and uterus), thyroid, non-Hodgkin lymphoma, and melanoma of the skin for women.

In New Jersey, the overall age-adjusted total cancer incidence rate for men was 588.2 per 100,000 for the years 2003-2007, with rates that decreased in 2004 and 2005 and then increased in 2006 and 2007. This change in total cancer incidence rates for men is largely driven by the changes in prostate cancer incidence rates for reasons currently not known. Total cancer incidence rates for black men continue their steady decline and were lower than for white men in 2007. Lung cancer and colorectal cancer incidence rates among men also continue to decline. Melanoma of the skin and kidney cancer incidence rates among men continue to slowly increase.

The age-adjusted total cancer incidence rates for New Jersey women remained stable from 2003 through 2007 with an average annual incidence rate of 445.3 per 100,000 women. Total cancer incidence rates for black women slightly decreased for this time period and continue to be lower compared to white women. Breast and lung cancer incidence rates among all women remained stable while colorectal cancer incidence rates continue to decline during this time period. Incidence rates for thyroid cancer and melanoma of the skin for women increased statewide, especially for white women.

New Jersey Hispanics continue to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population including lung, colorectal, breast, prostate, bladder, and melanoma of the skin. Hispanics also continued to have higher incidence rates for cervical, stomach and liver cancers compared with the general population.

A review of the incidence of benign and borderline brain and central nervous system tumors in New Jersey showed that they occurred mostly in intracranial meninges and the sellar region, while invasive brain tumors occurred mostly in the brain proper. This pattern was similar to the results seen in U.S. SEER data. New Jersey incidence data for 2004-2007 showed women had slightly higher rates compared to men for these types of tumors and rates were similar among whites and blacks. Women also had higher benign intracranial meningioma incidence rates compared to men for this same time period.

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 2002-2006, New Jersey incidence rates for all cancers combined continued to be higher than the U.S. rates. Both New Jersey men and women had higher incidence rates compared to the U.S. for the most common cancers with a few exceptions. New Jersey lung cancer incidence rates for all men combined, white men and black men were lower than the U.S. rates. Also, New Jersey breast cancer incidence rates were lower than the U.S. rates for black women, and melanoma of the skin incidence rates were similar to the U.S. rates for black men.

Among New Jersey residents, a total of 17,180 deaths occurred in 2006 for which cancer was designated on the death certificate as the underlying cause, compared to 17,171 reported cancer deaths in 2005. During the period 2003-2006, a total of 69,514 cancer deaths occurred among New Jersey residents, 48.8 percent among men and 51.2 percent among women. The top cancers with the highest age-adjusted mortality rates for 2003-2006 in New Jersey were lung, prostate, and colon and rectum for men; and lung, breast, and colon and rectum for women. Overall age-adjusted cancer mortality rates for men and women in New Jersey continued to decline, reflecting the continuing trends seen in U.S. mortality data.

New Jersey cancer mortality rates continued to be higher for men than for women. Cancer mortality rates for both black men and women continue to be higher compared to white men and women. Overall cancer mortality rates for New Jersey Hispanic men and women were lower than for New Jersey men and women as a whole, except for slightly higher mortality rates for liver cancer among Hispanic women and stomach cancer among both Hispanic men and women. Mortality rates were generally higher for Hispanic men compared with Hispanic women, which is consistent with the pattern seen among all races/ethnicities combined.

For the period 2002-2006, the New Jersey cancer mortality rates for men for all cancers combined, lung, and prostate cancer, were lower than the corresponding rates for the U.S. while the colorectal cancer mortality rate for men was slightly higher compared to the U.S. New Jersey lung, prostate, colorectal and total cancer mortality rates were also lower than the U.S. rates for both white and black men with the exception of the colorectal mortality rate for white men, which was higher. Among New Jersey women for the same time period, the cancer mortality rates for all sites combined, breast and colorectal cancers were higher compared to the U.S. New Jersey lung, breast, colorectal and total cancer mortality rates were higher than the U.S. rates for both white and black women with the exception of the lung mortality rate for white women, which was lower.

TECHNICAL NOTES

New Jersey State Cancer Registry (NJSCR)

NJSCR Overview

The objectives of the NJSCR are to:

- * monitor cancer trends in New Jersey,
- * promote scientific research,
- * respond to New Jersey residents about cancer concerns,
- * educate the public,
- * provide information for planning and evaluating cancer prevention and control activities, and
- * share and compare cancer data with other states and the nation.

The NJSCR is a population-based cancer incidence registry that serves the entire state of New Jersey which has a current estimated population of over 8.6 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the NJSCR by requiring electronic reporting, requiring abstracting by certified tumor registrars, and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. Benign and borderline brain tumors diagnosed on or after January 1, 2004 are reportable according to Public Law 107-260, the Benign Brain Tumor Cancer Registries Act, which was signed in October 2002. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O)*, 3rd edition for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a National Cancer Institute (NCI) SEER Registry.

NJSCR Data Quality

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each year 1995 through 2006. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2007 data, the completeness of case reporting was estimated as 108 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2007 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases: 1.4 percent;
- percent of unresolved duplicates: < 0.1 percent;
- percent of cases with unknown race: 2.3 percent;
- percent of cases with unknown county: 0.05 percent;
- number of cases with unknown age: 4; and
- number of cases with unknown gender: 1.

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to delayed reporting, ongoing editing and reviewing of the data. The 2006 incidence rate for total cancer in this report increased by 1.5% for both men and women compared with last year's report. The 2007 incidence rates are considered preliminary since case counts are expected to change by the time all data are complete.

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past few years, significant improvements have been realized in this regard.

For example, some of these improvements have resulted in better reporting of skin cancers such as melanoma. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting has improved the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

One limitation that could affect New Jersey cancer incidence data is the recent federal formal restrictions on the submission of cancer cases from Veteran's Health Administration (VA) hospitals to cancer registries. NJSCR received 0.6% of the total cases exclusively from VA hospitals for the years 2004 and earlier. Since then, the NJSCR received only 0.3% of the total cases from VA hospitals for 2005 and no cases for 2006 and 2007. The impact of missing VA hospital cases in New Jersey could result in underestimates of cancer incidence rates for men in 2005, 2006 and 2007.

Data Sources and Specifications

Incidence Data

New Jersey cancer incidence data were taken from the December 2009 analytic file of the NJSCR. All the counts and rates were tabulated using SEER*Stat Version 6.5 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the NCI. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America 2002-2006* (<http://www.naacr.org/cancerinnorthamerica>).

The cancer categories in this report are based on the primary site and histology data fields abstracted from the medical records. For detailed definitions of the cancer categories, please visit the SEER program website (http://www.seer.cancer.gov/siterecode/icdo3_d01272003/). We used the cancer site recode with mesothelioma and Kaposi sarcoma in separate categories.

The coding scheme for incident cancer cases in this report is derived from *International Classification of Diseases for Oncology, 3rd edition (ICD-O-3)*. There are some reportability changes from ICD-O-2 to ICD-O-3. When cases in 1979-2000 are converted from ICD-O-2 to ICD-O-3, some cancers (mainly ovarian cancer) yield an ICD-O-3 borderline behavior. Also, when 2001 or later cases are converted from ICD-O-3 to ICD-O-2, some cancers yield an ICD-O-2 borderline behavior. We used SEER behavior recode for analysis to select invasive cancers. For the definition, visit SEER Behavior Recode for Analysis on the SEER website: <http://www.seer.cancer.gov/behavrecode/>. Using this definition, only those invasive cancers that had a behavior of malignant in both ICD-O-2 and ICD-O-3 are presented in the tables, except the benign and borderline brain tumor table.

Exclusions

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2002-2006 is 120, representing 0.05% of the total case population. The small numbers of cases with unknown age or gender were also excluded from the

analyses. Since the number of records affected was very small, the rates were virtually unaffected by the non-inclusion of these records. Race-specific information is not shown separately for persons who are races other than white or black (including unknown race), but these persons are included in the “all races” data.

Only invasive cancers were included in the incidence tables 1 to 7, 9-10 and 21-22, except *in situ* bladder cancers were included. Invasive means that a case had malignant behavior in both ICD-O-2 and ICD-O-3. Some cancers were excluded from the analysis by this definition. Myelodysplastic syndrome, for example, was reclassified in ICD-O-3 (effective diagnosis year 2001) from nonmalignant to malignant; other cancers so reclassified include endometrial stromal sarcoma (low grade), papillary ependymoma, papillary meningioma, polycythemia vera, chronic myeloproliferative disease (NOS), myelosclerosis with myeloid metaplasia, essential thrombocythemia, refractory anemia, refractory anemia with sideroblasts, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation. In contrast, borderline tumors of the ovary were reclassified from malignant to nonmalignant at the same time, and these cancers were excluded from the analysis. Starting with diagnosis year 2001, pilocytic astrocytoma was reclassified as malignant and was not excluded.

Mortality Data

New Jersey cancer mortality data in 2003-2006 were obtained through the NCI's SEER Program from the National Center for Health Statistics (NCHS) and tabulated using SEER*Stat. At the time of this report, year 2007 mortality data were not yet available.

Cancer sites in mortality data were grouped according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on the SEER website (<http://seer.cancer.gov/codrecode/>). U.S. cancer mortality data were obtained from NAACCR's publication, *Cancer in North America 2002-2006* (<http://www.naaccr.org/cancerinnorthamerica>).

Population Data

The 2002-2007 New Jersey population estimates for this report were provided by the NCI's SEER Program release on November 20, 2009 and downloaded from the SEER's website (<http://www.seer.cancer.gov/popdata/download.html>). The population estimates represent a modification of the Vintage 2008 annual time series of July 1 county population estimates by age, sex, race and Hispanic origin produced by the U.S. Census Bureau's Population Estimates Program (<http://www.census.gov/popest/counties/asrh>) in collaboration with the NCHS, and with support from the NCI through an interagency agreement. The Vintage 2008 postcensal population estimates were produced after implementation of several methodologic changes by the Census Bureau with 2007 and later Vintage series. The net impact of the various methodologic changes is a downward shift of the Vintage 2008 postcensal population estimates when compared to those from the Vintage 2006 series. A downward shift in the net international migration estimates accounts for most of the change in the Vintage 2008 estimates.

In the 2000 Census, individuals were given the opportunity to categorize themselves as more than one race, as specified in the 1997 Office of Management and Budget (OMB) standards (http://www.whitehouse.gov/omb/fedreg/directive_15.html) for the collection of data on race and ethnicity. For the first time, individuals could "mark [X] one or more races to indicate what this person considers himself/herself to be." The population estimates incorporate new bridged single-race estimates for July 1, 2000 to July 1, 2007 that are derived from the original multiple race categories in the 2000 Census. These estimates result from bridging the 31 race categories used in Census 2000 to the four single race categories specified under the 1977 OMB standards. Race bridging is a method used to make multiple-race and single-race data collection systems sufficiently comparable to permit estimation and analysis of race-specific statistics. The bridged single-race estimates and a description of the methodology used to develop them appear on the NCHS website (<http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>).

Description of Algorithm for Designating Hispanic Ethnicity

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1994-2005.

In 2005, NAACCR made several revisions to NHIA, now NHIA version 2. The most significant change in NHIA version 2 was the addition of an option for registries to not apply the algorithm to counties in which the Hispanic population is less than five percent. The NJACR determined that this option did not enhance the accuracy of the NHIA and therefore opted not to apply this option. Thus, using NHIA version 2 will not affect the New Jersey cancer rates among Hispanics.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.

As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 21 percent for this time period, thereby correcting an under-identification of Hispanics. For a more complete description of the NHIA version 2 and a copy of the NHIA SAS program visit the following link at the NAACCR website: <http://www.naacr.org/datastandards>.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g., black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white or black are included in the white or black race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

Data Presentation

Suppression of Rates and Counts under Five

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than five as a way to ensure statistical reliability and patient confidentiality.

Calculation of Rates

All the counts and rates were tabulated using SEER*Stat Version 6.5 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 2002-2006* (<http://www.naaccr.org/cancerinnorthamerica>).

Age-adjusted Rates and the Year 2000 Standard

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard has been used in our last seven annual reports. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

In this report, the 2000 U.S. Standard Population (19 age groups-Census P25-1130) was used for age-adjustment instead of the 2000 U.S. Standard Million (19 age groups). This has been standard practice for all NCI SEER reports with incidence or mortality data for 2002 or later. This new population standard was created for use with single year of age population data.

Differences in the age-adjusted rates using the 2000 Standard Million and the new 2000 U.S. Standard Population are minimal. For further details, see SEER's website located at the following link: http://seer.cancer.gov/stdpopulations/single_age.html.

Rate Calculation Formulas

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

- r_a = the age-specific rate for age group a,
- n_a = the number of events (cancer diagnoses) in the age group during the time interval,
- t = the length of the time interval (in years), and
- P_a = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std. P_a}{\sum_{a=1}^n Std. P_a}$$

where

- R = the age-adjusted rate,
- r_a = the age-specific rate for age group a, and
- $Std.P_a$ = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

REFERENCES

- Breslow NE and Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies*. New York: Oxford University Press, 1987.
- Chiang CL. "Standard error of the age-adjusted death rate". In *Vital Statistics Special Reports, Volume 47, Number 9*. USDHEW, PHS, Washington, D.C. U.S. Government Printing office, 1961.
- Copeland G, Lake A, Firth R, et al. (eds). *Cancer in North America: 2002-2006. Volume One: Combined Cancer Incidence for the United States and Canada*. Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2009.
- Edwards BK, Ward E, Kohler BA, et al. Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates. *Cancer*. Published online Dec. 7, 2009. DOI: 10.1002/cncr.24760.
- Fritz A., Percy C. Implementing ICD-O-3: Impact of the New Edition. SEER Program, National Cancer Institute. [URL. http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf], accessed October 26, 2005]
- Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. *Vital Health Stat 2(135)*. 2003. [URL. http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf, accessed October 26, 2005]
- Martin, RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population". *Topics in Health Statistics*. Center for Health Statistics. 2000;01-02.
- National Center for Health Statistics. U.S. census population with bridged race categories, August 2008. [URL. <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>, accessed November 12, 2008]
- North American Association of Central Cancer Registries. Registry Operation Guidelines-Hispanic Identification. Springfield, Illinois: U.S. [URL. <http://www.naacr.org/datastandards>, accessed October 26, 2006]
- Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.
- Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.5.2. July 21, 2009.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2006) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released May 2009. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov)
SEER*Stat Database: Populations - Total U.S. (1969-2007), National Cancer Institute,
DCCPS, Surveillance Research Program, Cancer Statistics Branch, released November 2009.
[URL. <http://seer.cancer.gov/popdata/>, accessed December 1, 2009]

The United States Census Bureau. "Major differences in subject-matter content between 1990
and 2000 Census questionnaires-race", October 2003. [URL.
<http://www.census.gov/population/www/cen2000/90vs00.html>, accessed October 26, 2005]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New
Jersey Department of Health and Senior Services, June 2000. [URL.
<http://www.state.nj.us/health/cancer/hispanic/>, accessed October 26, 2005]

TABLES

Table 1. Age-adjusted Incidence Rates, Males All Races Combined

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 595.7 | 578.9 | 577.9 | 595.5 | 592.4 | 117,453 | 588.2 |
| Oral Cavity and Pharynx | 14.4 | 14.4 | 14.3 | 15.2 | 14.9 | 3,091 | 14.7 |
| Lip | 0.5 | 0.4 | 0.5 | 0.4 | 0.7 | 93 | 0.5 |
| Tongue | 4.5 | 4.5 | 4.3 | 5.2 | 4.8 | 995 | 4.7 |
| Salivary Gland | 1.6 | 1.5 | 1.7 | 1.9 | 1.8 | 340 | 1.7 |
| Floor of Mouth | 0.9 | 0.8 | 0.8 | 0.8 | 1.0 | 183 | 0.8 |
| Gum and Other Mouth | 1.9 | 1.9 | 1.7 | 1.9 | 1.8 | 379 | 1.9 |
| Nasopharynx | 1.0 | 0.5 | 1.1 | 0.6 | 0.9 | 170 | 0.8 |
| Tonsil | 2.1 | 2.2 | 2.1 | 2.2 | 2.0 | 478 | 2.2 |
| Oropharynx | 0.4 | 0.9 | 0.7 | 1.0 | 0.5 | 147 | 0.7 |
| Hypopharynx | 1.2 | 1.5 | 1.1 | 1.0 | 1.2 | 248 | 1.2 |
| Digestive System | 120.5 | 119.2 | 118.1 | 111.2 | 110.9 | 22,953 | 116.0 |
| Esophagus | 8.6 | 9.3 | 8.2 | 8.7 | 8.8 | 1,761 | 8.7 |
| Stomach | 12.8 | 12.9 | 12.8 | 11.8 | 11.7 | 2,436 | 12.4 |
| Small Intestine | 2.4 | 2.7 | 2.7 | 2.5 | 2.4 | 517 | 2.5 |
| Colon and Rectum | 67.9 | 64.8 | 65.0 | 58.3 | 57.0 | 12,273 | 62.6 |
| Colon excluding Rectum | 47.5 | 44.5 | 45.7 | 41.0 | 39.6 | 8,454 | 43.6 |
| Rectum and Rectosigmoid Junction | 20.4 | 20.3 | 19.3 | 17.3 | 17.4 | 3,819 | 18.9 |
| Anus, Anal Canal and Anorectum | 1.2 | 1.0 | 1.1 | 1.5 | 1.1 | 245 | 1.2 |
| Liver and Intrahepatic Bile Duct | 9.6 | 9.7 | 10.3 | 9.4 | 9.8 | 2,031 | 9.8 |
| Liver | 8.9 | 9.2 | 9.5 | 8.9 | 9.1 | 1,898 | 9.1 |
| Intrahepatic Bile Duct | 0.7 | 0.5 | 0.8 | 0.6 | 0.8 | 133 | 0.7 |
| Gallbladder | 1.4 | 0.9 | 0.8 | 1.3 | 0.9 | 206 | 1.1 |
| Pancreas | 13.7 | 14.4 | 14.1 | 14.7 | 15.6 | 2,852 | 14.5 |
| Respiratory System | 90.5 | 83.5 | 87.6 | 87.0 | 83.4 | 16,948 | 86.4 |
| Larynx | 7.2 | 6.7 | 6.8 | 7.8 | 6.2 | 1,422 | 6.9 |
| Lung and Bronchus | 82.0 | 75.7 | 79.7 | 78.1 | 76.1 | 15,294 | 78.3 |
| Bones and Joints | 1.2 | 1.2 | 1.0 | 1.2 | 1.4 | 253 | 1.2 |
| Soft Tissue (Including Heart) | 3.9 | 3.7 | 4.1 | 3.6 | 4.4 | 800 | 3.9 |
| Skin (Excluding Basal and Squamous) | 26.5 | 29.8 | 27.2 | 29.2 | 29.8 | 5,733 | 28.5 |
| Melanoma of the Skin | 24.9 | 27.7 | 25.1 | 27.0 | 27.6 | 5,339 | 26.5 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Breast | 1.5 | 1.8 | 1.9 | 1.3 | 2.1 | 337 | 1.7 |
| Male Genital System | 181.9 | 166.5 | 168.3 | 188.0 | 189.8 | 36,254 | 179.0 |
| Prostate | 174.9 | 159.3 | 162.5 | 181.3 | 183.0 | 34,856 | 172.3 |
| Testis | 5.7 | 6.3 | 4.9 | 5.7 | 5.6 | 1,192 | 5.7 |
| Penis | 1.1 | 0.7 | 0.6 | 0.7 | 0.9 | 158 | 0.8 |
| Urinary System | 65.9 | 70.8 | 68.9 | 71.1 | 70.4 | 13,571 | 69.4 |
| Urinary Bladder (Including in situ) | 44.9 | 48.8 | 46.5 | 47.5 | 46.0 | 8,949 | 46.7 |
| Kidney and Renal Pelvis | 19.8 | 20.9 | 21.0 | 21.7 | 22.8 | 4,350 | 21.2 |
| Ureter | 0.8 | 0.8 | 1.1 | 1.0 | 1.1 | 178 | 1.0 |
| Eye and Orbit | 1.0 | 1.2 | 0.8 | 1.1 | 1.0 | 207 | 1.0 |
| Brain and Other Nervous System | 9.1 | 8.0 | 8.9 | 8.9 | 8.0 | 1,777 | 8.6 |
| Brain | 8.4 | 7.6 | 8.4 | 8.4 | 7.5 | 1,654 | 8.0 |
| Endocrine System | 6.8 | 7.2 | 7.6 | 8.2 | 8.4 | 1,630 | 7.7 |
| Thyroid | 5.9 | 6.4 | 6.4 | 7.3 | 7.4 | 1,432 | 6.7 |
| Lymphomas | 30.2 | 29.1 | 29.4 | 29.5 | 27.9 | 5,896 | 29.2 |
| Hodgkin Lymphoma | 4.2 | 3.5 | 3.8 | 3.6 | 3.2 | 760 | 3.7 |
| Non-Hodgkin Lymphoma | 26.0 | 25.6 | 25.6 | 25.9 | 24.7 | 5,136 | 25.6 |
| Myelomas | 6.9 | 8.2 | 7.7 | 7.9 | 8.3 | 1,545 | 7.8 |
| Leukemias | 17.8 | 18.3 | 16.6 | 16.7 | 16.8 | 3,418 | 17.2 |
| Lymphocytic Leukemia | 8.8 | 10.0 | 8.5 | 8.8 | 8.5 | 1,785 | 8.9 |
| Acute Lymphocytic Leukemia | 1.4 | 2.1 | 2.0 | 2.0 | 2.0 | 395 | 1.9 |
| Chronic Lymphocytic Leukemia | 7.0 | 7.1 | 5.8 | 5.9 | 5.9 | 1,250 | 6.4 |
| Myeloid and Monocytic Leukemia | 8.2 | 7.5 | 7.2 | 7.1 | 7.3 | 1,473 | 7.5 |
| Acute Myeloid Leukemia | 4.9 | 5.0 | 4.8 | 4.9 | 4.7 | 953 | 4.9 |
| Acute Monocytic Leukemia | 0.5 | 0.2 | 0.3 | 0.4 | 0.5 | 74 | 0.4 |
| Chronic Myeloid Leukemia | 2.6 | 1.9 | 2.0 | 1.5 | 1.9 | 395 | 2.0 |
| Other Leukemia | 0.8 | 0.8 | 0.9 | 0.8 | 0.9 | 160 | 0.8 |
| Mesothelioma | 3.1 | 3.1 | 3.2 | 2.4 | 2.7 | 536 | 2.9 |
| Kaposi Sarcoma | 1.2 | 1.1 | 1.1 | 0.8 | 0.9 | 211 | 1.0 |
| Ill-Defined & Unspecified Sites | 13.2 | 11.7 | 11.2 | 12.0 | 11.3 | 2,293 | 11.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2. Age-adjusted Incidence Rates, Females All Races Combined

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 440.7 | 449.6 | 444.7 | 448.6 | 443.6 | 114,371 | 445.3 |
| Oral Cavity and Pharynx | 5.9 | 6.4 | 5.6 | 6.4 | 5.4 | 1,528 | 6.0 |
| Lip | 0.4 | 0.3 | 0.1 | 0.3 | 0.2 | 75 | 0.3 |
| Tongue | 1.7 | 1.7 | 1.6 | 1.9 | 1.6 | 441 | 1.7 |
| Salivary Gland | 0.9 | 1.2 | 1.1 | 1.0 | 1.1 | 259 | 1.0 |
| Floor of Mouth | 0.4 | 0.5 | 0.3 | 0.4 | 0.2 | 92 | 0.4 |
| Gum and Other Mouth | 1.2 | 1.2 | 1.2 | 1.3 | 1.1 | 319 | 1.2 |
| Nasopharynx | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 78 | 0.3 |
| Tonsil | 0.5 | 0.6 | 0.4 | 0.6 | 0.4 | 125 | 0.5 |
| Oropharynx | 0.2 | 0.3 | 0.1 | 0.2 | 0.2 | 54 | 0.2 |
| Hypopharynx | 0.2 | 0.3 | 0.2 | 0.3 | 0.2 | 61 | 0.2 |
| Digestive System | 81.2 | 78.6 | 78.0 | 75.4 | 73.3 | 20,804 | 77.3 |
| Esophagus | 2.5 | 2.0 | 1.9 | 2.3 | 1.9 | 569 | 2.1 |
| Stomach | 6.7 | 6.7 | 5.9 | 5.6 | 6.1 | 1,670 | 6.2 |
| Small Intestine | 1.9 | 1.8 | 2.0 | 1.9 | 1.4 | 470 | 1.8 |
| Colon and Rectum | 49.3 | 46.7 | 47.4 | 44.8 | 42.1 | 12,423 | 46.0 |
| Colon excluding Rectum | 37.2 | 34.8 | 35.5 | 32.8 | 31.1 | 9,315 | 34.2 |
| Rectum and Rectosigmoid Junction | 12.1 | 11.9 | 11.9 | 12.0 | 10.9 | 3,108 | 11.8 |
| Anus, Anal Canal and Anorectum | 1.5 | 1.8 | 1.8 | 1.6 | 1.7 | 431 | 1.7 |
| Liver and Intrahepatic Bile Duct | 3.2 | 3.3 | 2.9 | 3.4 | 3.6 | 875 | 3.3 |
| Liver | 2.7 | 2.7 | 2.4 | 2.7 | 2.9 | 716 | 2.7 |
| Intrahepatic Bile Duct | 0.4 | 0.6 | 0.5 | 0.7 | 0.7 | 159 | 0.6 |
| Gallbladder | 1.8 | 1.9 | 1.5 | 1.6 | 1.9 | 486 | 1.8 |
| Pancreas | 10.9 | 11.5 | 10.7 | 11.1 | 10.9 | 2,986 | 11.0 |
| Respiratory System | 57.9 | 57.2 | 59.0 | 59.1 | 58.9 | 15,247 | 58.4 |
| Larynx | 1.3 | 1.5 | 1.2 | 1.4 | 1.6 | 357 | 1.4 |
| Lung and Bronchus | 55.9 | 55.0 | 57.0 | 57.0 | 56.6 | 14,702 | 56.3 |
| Bones and Joints | 1.1 | 1.2 | 0.9 | 0.8 | 0.8 | 214 | 1.0 |
| Soft Tissue (Including Heart) | 2.8 | 3.3 | 3.0 | 2.8 | 2.7 | 721 | 2.9 |
| Skin (Excluding Basal and Squamous) | 15.9 | 17.5 | 19.6 | 19.6 | 19.9 | 4,564 | 18.5 |
| Melanoma of the Skin | 14.8 | 16.3 | 18.4 | 18.5 | 18.7 | 4,266 | 17.3 |
| Breast (Invasive) | 126.7 | 131.4 | 127.1 | 127.5 | 129.3 | 32,495 | 128.4 |
| In situ (not included in All Sites) | 37.0 | 36.3 | 35.2 | 39.4 | 38.7 | 9,280 | 37.3 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|------|------|------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Female Genital System | 55.5 | 54.1 | 55.5 | 58.5 | 56.8 | 14,211 | 56.1 |
| Cervix Uteri | 9.6 | 9.5 | 8.5 | 9.5 | 9.2 | 2,196 | 9.3 |
| Corpus and Uterus, NOS | 27.4 | 27.5 | 29.5 | 30.1 | 30.3 | 7,427 | 29.0 |
| Corpus Uteri | 26.4 | 26.6 | 28.6 | 29.1 | 29.6 | 7,195 | 28.1 |
| Uterus, NOS | 1.0 | 0.9 | 0.8 | 1.0 | 0.7 | 232 | 0.9 |
| Ovary | 14.7 | 13.7 | 14.0 | 14.8 | 13.3 | 3,606 | 14.1 |
| Vagina | 0.8 | 0.6 | 0.8 | 0.8 | 0.7 | 193 | 0.7 |
| Vulva | 2.3 | 2.1 | 2.1 | 2.4 | 2.4 | 596 | 2.3 |
| Urinary System | 21.3 | 25.1 | 23.4 | 23.1 | 22.9 | 6,101 | 23.2 |
| Urinary Bladder (Including in situ) | 11.3 | 13.6 | 11.9 | 12.2 | 11.6 | 3,265 | 12.1 |
| Kidney and Renal Pelvis | 9.5 | 11.0 | 10.9 | 10.3 | 10.5 | 2,674 | 10.4 |
| Ureter | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 121 | 0.5 |
| Eye and Orbit | 0.6 | 0.6 | 0.7 | 0.8 | 0.6 | 158 | 0.6 |
| Brain and Other Nervous System | 6.0 | 6.7 | 5.7 | 5.5 | 6.1 | 1,458 | 6.0 |
| Brain | 5.1 | 6.1 | 5.1 | 5.0 | 5.4 | 1,301 | 5.4 |
| Endocrine System | 18.8 | 19.9 | 20.3 | 22.3 | 22.5 | 4,841 | 20.8 |
| Thyroid | 17.8 | 19.2 | 19.5 | 21.8 | 21.8 | 4,663 | 20.0 |
| Lymphomas | 21.3 | 21.0 | 20.6 | 20.8 | 20.1 | 5,258 | 20.8 |
| Hodgkin Lymphoma | 3.2 | 3.0 | 3.5 | 2.9 | 2.9 | 689 | 3.1 |
| Non-Hodgkin Lymphoma | 18.1 | 17.9 | 17.1 | 17.9 | 17.2 | 4,569 | 17.6 |
| Myelomas | 4.8 | 4.9 | 5.6 | 5.2 | 5.0 | 1,348 | 5.1 |
| Leukemias | 10.3 | 10.6 | 9.6 | 10.8 | 10.1 | 2,621 | 10.3 |
| Lymphocytic Leukemia | 5.0 | 5.3 | 4.9 | 5.1 | 4.8 | 1,277 | 5.0 |
| Acute Lymphocytic Leukemia | 1.6 | 1.4 | 1.3 | 1.5 | 1.8 | 321 | 1.5 |
| Chronic Lymphocytic Leukemia | 3.2 | 3.6 | 3.3 | 3.4 | 2.8 | 879 | 3.2 |
| Myeloid and Monocytic Leukemia | 4.7 | 4.8 | 3.9 | 5.1 | 4.8 | 1,188 | 4.7 |
| Acute Myeloid Leukemia | 3.1 | 3.4 | 2.8 | 3.3 | 3.1 | 805 | 3.2 |
| Acute Monocytic Leukemia | 0.2 | 0.1 | 0.1 | 0.2 | 0.3 | 49 | 0.2 |
| Chronic Myeloid Leukemia | 1.3 | 1.2 | 0.9 | 1.4 | 1.1 | 301 | 1.2 |
| Other Leukemia | 0.6 | 0.5 | 0.7 | 0.5 | 0.5 | 156 | 0.6 |
| Mesothelioma | 0.6 | 0.5 | 0.6 | 0.7 | 0.6 | 165 | 0.6 |
| Kaposi Sarcoma | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 40 | 0.1 |
| Ill-Defined & Unspecified Sites | 9.8 | 10.6 | 9.2 | 9.1 | 8.4 | 2,597 | 9.4 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3. Age-adjusted Incidence Rates, White Males

| Cancer Site | Rates | | | | | Total 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 590.5 | 572.9 | 576.7 | 595.7 | 591.2 | 98,625 | 585.5 |
| Oral Cavity and Pharynx | 14.5 | 13.9 | 14.5 | 15.3 | 15.0 | 2,572 | 14.7 |
| Lip | 0.5 | 0.5 | 0.6 | 0.3 | 0.7 | 86 | 0.5 |
| Tongue | 4.5 | 4.6 | 4.4 | 5.4 | 5.1 | 857 | 4.8 |
| Salivary Gland | 1.8 | 1.4 | 1.8 | 2.1 | 2.0 | 303 | 1.8 |
| Floor of Mouth | 0.9 | 0.7 | 0.9 | 0.7 | 0.9 | 147 | 0.8 |
| Gum and Other Mouth | 1.9 | 1.9 | 1.6 | 1.8 | 1.7 | 303 | 1.8 |
| Nasopharynx | 0.8 | 0.4 | 0.7 | 0.3 | 0.7 | 101 | 0.6 |
| Tonsil | 2.3 | 2.1 | 2.4 | 2.4 | 2.1 | 414 | 2.3 |
| Oropharynx | 0.5 | 0.9 | 0.7 | 1.1 | 0.5 | 130 | 0.7 |
| Hypopharynx | 1.1 | 1.3 | 1.1 | 0.8 | 1.1 | 186 | 1.1 |
| Digestive System | 118.2 | 117.2 | 116.8 | 110.4 | 109.5 | 19,205 | 114.5 |
| Esophagus | 8.4 | 9.4 | 8.2 | 8.8 | 9.1 | 1,497 | 8.8 |
| Stomach | 12.0 | 11.9 | 11.9 | 11.1 | 10.6 | 1,916 | 11.5 |
| Small Intestine | 2.4 | 2.6 | 2.4 | 2.5 | 2.3 | 418 | 2.4 |
| Colon and Rectum | 67.1 | 65.2 | 65.2 | 58.8 | 57.0 | 10,446 | 62.7 |
| Colon excluding Rectum | 46.6 | 45.0 | 45.9 | 41.3 | 39.9 | 7,231 | 43.7 |
| Rectum and Rectosigmoid Junction | 20.5 | 20.3 | 19.3 | 17.5 | 17.1 | 3,215 | 18.9 |
| Anus, Anal Canal and Anorectum | 1.2 | 1.0 | 1.0 | 1.5 | 1.0 | 199 | 1.1 |
| Liver and Intrahepatic Bile Duct | 8.7 | 8.5 | 10.0 | 8.7 | 9.3 | 1,569 | 9.1 |
| Liver | 7.9 | 8.0 | 9.3 | 8.1 | 8.6 | 1,456 | 8.4 |
| Intrahepatic Bile Duct | 0.8 | 0.5 | 0.7 | 0.6 | 0.7 | 113 | 0.7 |
| Gallbladder | 1.4 | 0.9 | 0.8 | 1.1 | 0.9 | 168 | 1.0 |
| Pancreas | 13.9 | 14.4 | 14.0 | 14.9 | 15.8 | 2,446 | 14.6 |
| Respiratory System | 89.9 | 83.5 | 87.5 | 88.4 | 83.9 | 14,472 | 86.7 |
| Larynx | 7.2 | 6.5 | 6.7 | 7.7 | 5.9 | 1,171 | 6.8 |
| Lung and Bronchus | 81.3 | 76.0 | 79.7 | 79.6 | 76.8 | 13,104 | 78.7 |
| Bones and Joints | 1.2 | 1.3 | 1.1 | 1.2 | 1.5 | 204 | 1.2 |
| Soft Tissue (Including Heart) | 3.8 | 3.5 | 4.2 | 3.6 | 4.8 | 661 | 4.0 |
| Skin (Excluding Basal and Squamous) | 30.3 | 33.6 | 31.5 | 32.3 | 32.8 | 5,418 | 32.1 |
| Melanoma of the Skin | 28.6 | 31.5 | 29.3 | 29.9 | 30.6 | 5,067 | 30.0 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3 (continued). Age-adjusted Incidence Rates, White Males

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Breast | 1.5 | 1.8 | 1.9 | 1.3 | 2.0 | 284 | 1.7 |
| Male Genital System | 169.1 | 153.9 | 157.8 | 178.2 | 178.5 | 28,597 | 167.6 |
| Prostate | 160.8 | 145.5 | 151.0 | 170.2 | 170.1 | 27,309 | 159.6 |
| Testis | 6.9 | 7.6 | 5.9 | 7.0 | 7.2 | 1,109 | 6.9 |
| Penis | 1.1 | 0.7 | 0.7 | 0.8 | 0.9 | 139 | 0.8 |
| Urinary System | 70.0 | 74.6 | 72.9 | 74.2 | 74.0 | 12,184 | 73.1 |
| Urinary Bladder (Including in situ) | 48.9 | 51.7 | 49.8 | 50.4 | 48.4 | 8,207 | 49.8 |
| Kidney and Renal Pelvis | 19.9 | 21.7 | 21.7 | 21.9 | 23.8 | 3,734 | 21.8 |
| Ureter | 0.8 | 0.9 | 1.1 | 1.1 | 1.2 | 163 | 1.0 |
| Eye and Orbit | 1.2 | 1.2 | 0.9 | 1.3 | 1.0 | 192 | 1.1 |
| Brain and Other Nervous System | 9.9 | 8.9 | 9.6 | 9.6 | 8.6 | 1,563 | 9.3 |
| Brain | 9.0 | 8.4 | 9.0 | 9.0 | 8.1 | 1,461 | 8.7 |
| Endocrine System | 7.3 | 7.6 | 7.7 | 8.8 | 9.3 | 1,400 | 8.1 |
| Thyroid | 6.4 | 6.8 | 6.7 | 7.9 | 8.2 | 1,246 | 7.2 |
| Lymphomas | 31.4 | 29.9 | 30.2 | 30.7 | 29.5 | 5,081 | 30.3 |
| Hodgkin Lymphoma | 4.7 | 3.5 | 4.0 | 3.6 | 3.4 | 628 | 3.8 |
| Non-Hodgkin Lymphoma | 26.6 | 26.5 | 26.2 | 27.1 | 26.1 | 4,453 | 26.5 |
| Myelomas | 6.3 | 7.5 | 7.2 | 7.5 | 7.5 | 1,211 | 7.2 |
| Leukemias | 18.4 | 18.6 | 17.6 | 17.6 | 17.8 | 2,977 | 18.0 |
| Lymphocytic Leukemia | 9.3 | 10.3 | 9.1 | 9.5 | 8.9 | 1,560 | 9.4 |
| Acute Lymphocytic Leukemia | 1.5 | 2.3 | 2.1 | 2.2 | 2.1 | 323 | 2.0 |
| Chronic Lymphocytic Leukemia | 7.4 | 7.3 | 6.2 | 6.3 | 6.0 | 1,113 | 6.7 |
| Myeloid and Monocytic Leukemia | 8.3 | 7.5 | 7.7 | 7.3 | 7.9 | 1,284 | 7.7 |
| Acute Myeloid Leukemia | 5.1 | 5.2 | 5.2 | 5.2 | 5.0 | 848 | 5.1 |
| Acute Monocytic Leukemia | 0.5 | 0.3 | 0.3 | 0.4 | 0.6 | 68 | 0.4 |
| Chronic Myeloid Leukemia | 2.5 | 1.7 | 2.0 | 1.5 | 2.1 | 326 | 1.9 |
| Other Leukemia | 0.7 | 0.8 | 0.8 | 0.8 | 1.0 | 133 | 0.8 |
| Mesothelioma | 3.3 | 3.3 | 3.4 | 2.5 | 3.0 | 503 | 3.1 |
| Kaposi Sarcoma | 0.9 | 0.9 | 0.9 | 0.6 | 0.8 | 137 | 0.8 |
| Ill-Defined & Unspecified Sites | 13.2 | 11.5 | 11.1 | 12.1 | 11.6 | 1,964 | 11.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4. Age-adjusted Incidence Rates, White Females

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 452.4 | 463.9 | 459.4 | 460.1 | 457.0 | 97,456 | 458.4 |
| Oral Cavity and Pharynx | 5.4 | 6.7 | 5.6 | 6.3 | 5.4 | 1,261 | 5.9 |
| Lip | 0.4 | 0.3 | 0.2 | 0.4 | 0.2 | 69 | 0.3 |
| Tongue | 1.7 | 1.8 | 1.8 | 2.0 | 1.6 | 380 | 1.8 |
| Salivary Gland | 0.8 | 1.2 | 1.0 | 1.0 | 1.0 | 206 | 1.0 |
| Floor of Mouth | 0.4 | 0.5 | 0.4 | 0.3 | 0.2 | 79 | 0.4 |
| Gum and Other Mouth | 1.0 | 1.3 | 1.2 | 1.3 | 0.9 | 262 | 1.2 |
| Nasopharynx | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 47 | 0.2 |
| Tonsil | 0.5 | 0.7 | 0.3 | 0.6 | 0.5 | 106 | 0.5 |
| Oropharynx | 0.2 | 0.3 | - | 0.2 | 0.2 | 43 | 0.2 |
| Hypopharynx | 0.1 | 0.3 | 0.3 | 0.2 | 0.2 | 49 | 0.2 |
| Digestive System | 79.3 | 77.1 | 76.7 | 73.5 | 71.4 | 17,343 | 75.6 |
| Esophagus | 2.3 | 1.9 | 1.7 | 2.2 | 2.0 | 462 | 2.0 |
| Stomach | 6.5 | 6.3 | 5.1 | 4.8 | 5.5 | 1,297 | 5.6 |
| Small Intestine | 1.7 | 1.8 | 2.0 | 1.8 | 1.3 | 373 | 1.7 |
| Colon and Rectum | 47.9 | 46.5 | 47.3 | 44.0 | 41.4 | 10,457 | 45.4 |
| Colon excluding Rectum | 36.0 | 34.3 | 35.2 | 32.4 | 30.2 | 7,836 | 33.6 |
| Rectum and Rectosigmoid Junction | 11.9 | 12.2 | 12.1 | 11.6 | 11.2 | 2,621 | 11.8 |
| Anus, Anal Canal and Anorectum | 1.5 | 1.9 | 1.9 | 1.6 | 1.9 | 368 | 1.7 |
| Liver and Intrahepatic Bile Duct | 2.9 | 2.9 | 2.8 | 3.3 | 3.1 | 690 | 3.0 |
| Liver | 2.6 | 2.3 | 2.2 | 2.6 | 2.4 | 552 | 2.4 |
| Intrahepatic Bile Duct | 0.3 | 0.6 | 0.6 | 0.8 | 0.7 | 138 | 0.6 |
| Gallbladder | 1.8 | 1.7 | 1.5 | 1.5 | 1.7 | 389 | 1.6 |
| Pancreas | 11.0 | 11.5 | 10.8 | 11.0 | 10.8 | 2,544 | 11.0 |
| Respiratory System | 59.9 | 58.4 | 61.6 | 61.7 | 61.7 | 13,322 | 60.6 |
| Larynx | 1.2 | 1.5 | 1.2 | 1.4 | 1.5 | 293 | 1.4 |
| Lung and Bronchus | 58.0 | 56.2 | 59.5 | 59.5 | 59.5 | 12,870 | 58.5 |
| Bones and Joints | 1.2 | 1.2 | 1.0 | 0.8 | 0.9 | 178 | 1.0 |
| Soft Tissue (Including Heart) | 2.6 | 3.2 | 3.2 | 2.8 | 2.8 | 585 | 2.9 |
| Skin (Excluding Basal and Squamous) | 18.5 | 20.6 | 23.6 | 22.2 | 22.8 | 4,264 | 21.5 |
| Melanoma of the Skin | 17.4 | 19.3 | 22.5 | 21.0 | 21.4 | 4,010 | 20.3 |
| Breast (Invasive) | 131.4 | 137.5 | 131.3 | 131.4 | 133.2 | 27,549 | 132.9 |
| In situ (not included in All Sites) | 38.6 | 38.4 | 36.2 | 40.7 | 40.2 | 7,808 | 38.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4 (continued). Age-adjusted Incidence Rates, White Females

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|------|------|------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Female Genital System | 56.9 | 55.8 | 57.4 | 60.2 | 58.3 | 11,990 | 57.8 |
| Cervix Uteri | 9.3 | 9.1 | 8.1 | 9.1 | 8.6 | 1,638 | 8.8 |
| Corpus and Uterus, NOS | 28.4 | 29.2 | 30.9 | 31.7 | 31.5 | 6,406 | 30.3 |
| Corpus Uteri | 27.4 | 28.3 | 30.2 | 30.7 | 30.8 | 6,218 | 29.5 |
| Uterus, NOS | 1.1 | 0.9 | 0.7 | 0.9 | 0.6 | 188 | 0.8 |
| Ovary | 15.4 | 14.3 | 15.0 | 15.5 | 14.0 | 3,120 | 14.8 |
| Vagina | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 144 | 0.6 |
| Vulva | 2.4 | 2.1 | 2.2 | 2.5 | 2.6 | 524 | 2.4 |
| Urinary System | 22.0 | 26.6 | 24.6 | 23.3 | 23.9 | 5,329 | 24.1 |
| Urinary Bladder (including in situ) | 11.9 | 14.4 | 12.8 | 12.3 | 12.2 | 2,907 | 12.7 |
| Kidney and Renal Pelvis | 9.6 | 11.6 | 11.2 | 10.5 | 10.9 | 2,287 | 10.8 |
| Ureter | 0.4 | 0.5 | 0.5 | 0.4 | 0.6 | 108 | 0.5 |
| Eye and Orbit | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 149 | 0.7 |
| Brain and Other Nervous System | 6.9 | 7.1 | 6.2 | 5.8 | 6.7 | 1,279 | 6.5 |
| Brain | 5.9 | 6.6 | 5.6 | 5.5 | 6.0 | 1,160 | 5.9 |
| Endocrine System | 20.0 | 21.7 | 21.5 | 23.9 | 24.2 | 4,050 | 22.2 |
| Thyroid | 19.2 | 21.0 | 20.6 | 23.4 | 23.5 | 3,915 | 21.5 |
| Lymphomas | 22.1 | 21.7 | 21.5 | 22.1 | 21.3 | 4,559 | 21.7 |
| Hodgkin Lymphoma | 3.3 | 3.3 | 3.8 | 3.2 | 3.3 | 580 | 3.4 |
| Non-Hodgkin Lymphoma | 18.8 | 18.5 | 17.6 | 18.8 | 17.9 | 3,979 | 18.3 |
| Myelomas | 4.2 | 4.0 | 4.8 | 4.4 | 4.5 | 980 | 4.4 |
| Leukemias | 10.6 | 10.7 | 9.7 | 10.9 | 10.5 | 2,231 | 10.5 |
| Lymphocytic Leukemia | 5.3 | 5.3 | 5.3 | 5.2 | 5.2 | 1,110 | 5.3 |
| Acute Lymphocytic Leukemia | 1.8 | 1.4 | 1.3 | 1.5 | 2.0 | 264 | 1.6 |
| Chronic Lymphocytic Leukemia | 3.3 | 3.5 | 3.5 | 3.5 | 3.0 | 780 | 3.4 |
| Myeloid and Monocytic Leukemia | 4.8 | 4.8 | 3.8 | 5.2 | 4.8 | 992 | 4.7 |
| Acute Myeloid Leukemia | 3.1 | 3.4 | 2.8 | 3.3 | 3.2 | 674 | 3.2 |
| Acute Monocytic Leukemia | 0.2 | 0.2 | 0.1 | 0.3 | 0.3 | 47 | 0.2 |
| Chronic Myeloid Leukemia | 1.4 | 1.2 | 0.7 | 1.4 | 1.0 | 243 | 1.2 |
| Other Leukemia | 0.5 | 0.6 | 0.6 | 0.5 | 0.5 | 129 | 0.5 |
| Mesothelioma | 0.7 | 0.5 | 0.7 | 0.8 | 0.6 | 151 | 0.7 |
| Kaposi Sarcoma | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 30 | 0.1 |
| Ill-Defined & Unspecified Sites | 9.8 | 10.4 | 9.1 | 9.1 | 8.1 | 2,206 | 9.3 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5. Age-adjusted Incidence Rates, Black Males

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 681.2 | 650.1 | 618.2 | 597.4 | 577.2 | 12,893 | 623.6 |
| Oral Cavity and Pharynx | 14.5 | 22.4 | 12.8 | 14.8 | 14.1 | 358 | 15.7 |
| Lip | 0.0 | 0.0 | 0.0 | 0.0 | - | - | - |
| Tongue | 4.4 | 6.4 | 3.2 | 5.4 | 3.3 | 102 | 4.5 |
| Salivary Gland | - | 2.6 | 0.8 | - | - | 26 | 1.2 |
| Floor of Mouth | - | 1.1 | - | 1.1 | 1.5 | 24 | 1.0 |
| Gum and Other Mouth | 1.7 | 1.2 | 1.9 | 1.7 | 1.6 | 37 | 1.6 |
| Nasopharynx | 1.1 | 1.3 | 1.7 | 1.0 | 0.9 | 29 | 1.2 |
| Tonsil | 2.3 | 3.9 | 1.5 | 2.1 | 2.4 | 60 | 2.4 |
| Oropharynx | - | 1.3 | - | - | - | 15 | 0.7 |
| Hypopharynx | 1.9 | 3.8 | 1.6 | 2.3 | 2.9 | 54 | 2.5 |
| Digestive System | 148.3 | 132.2 | 127.6 | 124.7 | 127.2 | 2,619 | 131.7 |
| Esophagus | 13.2 | 10.7 | 11.3 | 9.5 | 9.4 | 222 | 10.8 |
| Stomach | 16.9 | 17.4 | 16.9 | 16.9 | 18.5 | 327 | 17.3 |
| Small Intestine | 2.8 | 3.5 | 3.9 | 2.2 | 4.2 | 71 | 3.3 |
| Colon and Rectum | 82.6 | 67.2 | 67.5 | 60.5 | 59.2 | 1,300 | 67.1 |
| Colon excluding Rectum | 64.7 | 47.8 | 50.6 | 43.2 | 42.6 | 932 | 49.5 |
| Rectum and Rectosigmoid Junction | 17.9 | 19.4 | 16.9 | 17.3 | 16.5 | 368 | 17.6 |
| Anus, Anal Canal and Anorectum | 1.5 | 1.5 | 1.5 | 1.4 | 1.8 | 40 | 1.5 |
| Liver and Intrahepatic Bile Duct | 12.2 | 14.1 | 7.7 | 12.7 | 10.9 | 270 | 11.5 |
| Liver | 11.6 | 13.9 | 7.0 | 12.2 | 9.7 | 256 | 10.8 |
| Intrahepatic Bile Duct | - | - | - | - | 1.2 | 14 | 0.6 |
| Gallbladder | - | - | - | 2.3 | - | 24 | 1.3 |
| Pancreas | 16.1 | 14.3 | 15.3 | 16.8 | 17.5 | 309 | 16.0 |
| Respiratory System | 110.8 | 101.2 | 101.1 | 93.6 | 96.7 | 2,011 | 100.5 |
| Larynx | 9.3 | 11.8 | 8.9 | 10.4 | 9.9 | 217 | 10.1 |
| Lung and Bronchus | 101.1 | 88.5 | 90.9 | 82.4 | 85.4 | 1,775 | 89.5 |
| Bones and Joints | 1.3 | 1.0 | 1.2 | 1.1 | 1.3 | 35 | 1.2 |
| Soft Tissue (Including Heart) | 5.4 | 5.4 | 4.2 | 4.3 | 2.8 | 103 | 4.4 |
| Skin (Excluding Basal and Squamous) | 1.3 | 2.0 | 3.6 | 1.8 | 2.4 | 45 | 2.2 |
| Melanoma of the Skin | - | 1.6 | 1.9 | 1.1 | - | 23 | 1.3 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5 (continued). Age-adjusted Incidence Rates, Black Males

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Breast | 1.4 | 2.3 | 2.3 | 2.3 | 3.0 | 46 | 2.3 |
| Male Genital System | 284.9 | 257.4 | 240.4 | 245.1 | 229.3 | 5,203 | 250.8 |
| Prostate | 281.6 | 255.3 | 238.8 | 243.0 | 228.3 | 5,151 | 248.8 |
| Testis | 2.1 | 1.6 | 0.9 | 0.9 | - | 37 | 1.2 |
| Penis | - | - | 0.0 | - | - | 11 | 0.5 |
| Urinary System | 36.8 | 42.5 | 44.4 | 46.6 | 39.8 | 847 | 42.1 |
| Urinary Bladder (Including in situ) | 14.3 | 24.0 | 21.9 | 21.0 | 19.6 | 371 | 20.2 |
| Kidney and Renal Pelvis | 21.7 | 17.6 | 21.5 | 24.4 | 19.8 | 458 | 21.0 |
| Ureter | - | - | - | - | - | 8 | 0.4 |
| Eye and Orbit | - | - | - | - | - | 7 | 0.2 |
| Brain and Other Nervous System | 4.9 | 3.7 | 5.6 | 5.5 | 3.8 | 118 | 4.7 |
| Brain | 4.5 | 3.4 | 5.5 | 5.3 | 3.3 | 109 | 4.4 |
| Endocrine System | 4.0 | 3.2 | 7.0 | 4.3 | 3.7 | 107 | 4.5 |
| Thyroid | 3.4 | 2.8 | 4.4 | 3.5 | 3.1 | 82 | 3.5 |
| Lymphomas | 21.3 | 25.1 | 24.4 | 19.3 | 15.1 | 522 | 21.0 |
| Hodgkin Lymphoma | 2.2 | 4.6 | 2.8 | 4.1 | 2.1 | 93 | 3.1 |
| Non-Hodgkin Lymphoma | 19.1 | 20.5 | 21.6 | 15.2 | 13.0 | 429 | 17.8 |
| Myelomas | 13.4 | 17.0 | 12.6 | 10.5 | 15.0 | 269 | 13.7 |
| Leukemias | 14.3 | 15.2 | 11.6 | 9.3 | 10.2 | 260 | 12.1 |
| Lymphocytic Leukemia | 4.5 | 6.9 | 5.6 | 3.7 | 5.6 | 116 | 5.3 |
| Acute Lymphocytic Leukemia | 1.7 | 1.1 | 1.5 | 1.3 | 0.8 | 40 | 1.3 |
| Chronic Lymphocytic Leukemia | 2.8 | 3.8 | 3.6 | 2.4 | 4.2 | 65 | 3.4 |
| Myeloid and Monocytic Leukemia | 8.4 | 7.7 | 5.0 | 4.7 | 3.9 | 125 | 5.9 |
| Acute Myeloid Leukemia | 4.0 | 3.7 | 2.7 | 2.8 | 2.5 | 68 | 3.1 |
| Acute Monocytic Leukemia | - | 0.0 | 0.0 | - | 0.0 | - | - |
| Chronic Myeloid Leukemia | 3.9 | 3.2 | 2.3 | 1.4 | - | 48 | 2.4 |
| Other Leukemia | 1.4 | - | - | - | - | 19 | 0.9 |
| Mesothelioma | - | 1.4 | 2.4 | - | - | 23 | 1.4 |
| Kaposi Sarcoma | 2.3 | 3.1 | 2.7 | 1.5 | 1.2 | 61 | 2.2 |
| Ill-Defined & Unspecified Sites | 15.0 | 14.9 | 14.2 | 11.6 | 10.2 | 259 | 13.1 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6. Age-adjusted Incidence Rates, Black Females

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| All Sites | 403.9 | 400.8 | 395.0 | 394.1 | 390.3 | 11,929 | 396.7 |
| Oral Cavity and Pharynx | 8.3 | 5.0 | 4.5 | 5.2 | 5.4 | 176 | 5.7 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 1.5 | 1.0 | - | 1.7 | 0.9 | 35 | 1.1 |
| Salivary Gland | 1.1 | 1.0 | 1.6 | 0.9 | 1.5 | 40 | 1.2 |
| Floor of Mouth | - | - | - | - | - | 8 | 0.3 |
| Gum and Other Mouth | 2.5 | - | 1.0 | 0.8 | 1.6 | 38 | 1.3 |
| Nasopharynx | - | - | - | - | 0.7 | 17 | 0.5 |
| Tonsil | 0.9 | - | - | - | - | 15 | 0.5 |
| Oropharynx | - | - | - | - | - | 10 | 0.3 |
| Hypopharynx | - | - | - | - | - | 8 | 0.2 |
| Digestive System | 95.9 | 89.1 | 90.3 | 90.3 | 90.3 | 2,630 | 91.1 |
| Esophagus | 3.6 | 2.9 | 3.6 | 2.7 | 2.6 | 91 | 3.1 |
| Stomach | 8.1 | 9.0 | 10.8 | 9.6 | 8.8 | 259 | 9.3 |
| Small Intestine | 3.7 | 1.6 | 2.4 | 3.1 | 2.4 | 79 | 2.7 |
| Colon and Rectum | 57.3 | 50.3 | 50.7 | 52.3 | 49.1 | 1,502 | 51.9 |
| Colon excluding Rectum | 46.3 | 39.8 | 39.6 | 37.6 | 38.6 | 1,158 | 40.3 |
| Rectum and Rectosigmoid Junction | 11.0 | 10.5 | 11.1 | 14.6 | 10.5 | 344 | 11.6 |
| Anus, Anal Canal and Anorectum | 2.2 | 1.6 | 2.4 | 2.2 | 1.3 | 58 | 1.9 |
| Liver and Intrahepatic Bile Duct | 4.2 | 4.7 | 2.7 | 3.0 | 6.1 | 125 | 4.2 |
| Liver | 3.4 | 4.0 | 2.4 | 2.7 | 5.1 | 107 | 3.5 |
| Intrahepatic Bile Duct | - | - | - | - | 1.0 | 18 | 0.6 |
| Gallbladder | 2.8 | 2.4 | 2.0 | 2.3 | 3.6 | 73 | 2.6 |
| Pancreas | 12.0 | 13.7 | 11.6 | 13.0 | 14.0 | 363 | 12.9 |
| Respiratory System | 54.4 | 60.1 | 53.6 | 52.7 | 51.0 | 1,585 | 54.3 |
| Larynx | 2.4 | 2.0 | 1.0 | 1.4 | 2.6 | 56 | 1.8 |
| Lung and Bronchus | 51.8 | 57.4 | 52.0 | 50.4 | 48.0 | 1,512 | 51.9 |
| Bones and Joints | 0.9 | 1.1 | 0.9 | - | - | 25 | 0.8 |
| Soft Tissue (Including Heart) | 4.3 | 3.2 | 2.1 | 2.9 | 2.4 | 97 | 3.0 |
| Skin (Excluding Basal and Squamous) | 3.1 | 2.5 | 2.4 | 2.2 | 1.6 | 71 | 2.4 |
| Melanoma of the Skin | 1.5 | 1.4 | 0.8 | 1.4 | 0.9 | 35 | 1.2 |
| Breast (Invasive) | 107.6 | 105.6 | 110.1 | 109.0 | 117.0 | 3,415 | 109.9 |
| In situ (not included in All Sites) | 27.5 | 26.3 | 27.1 | 26.6 | 30.1 | 862 | 27.5 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6 (continued). Age-adjusted Incidence Rates, Black Females

| Cancer Site | Rates | | | | | Cases 2003-2007 | Rates |
|--|-------|------|------|------|-----------------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 Prelim. | | |
| Female Genital System | 53.8 | 48.0 | 50.9 | 49.5 | 49.9 | 1,552 | 50.4 |
| Cervix Uteri | 13.3 | 14.3 | 12.6 | 12.1 | 13.3 | 421 | 13.1 |
| Corpus and Uterus, NOS | 24.3 | 19.6 | 24.0 | 21.9 | 24.2 | 690 | 22.8 |
| Corpus Uteri | 23.9 | 18.0 | 22.0 | 20.9 | 23.1 | 653 | 21.6 |
| Uterus, NOS | - | 1.5 | 2.0 | 1.1 | 1.1 | 37 | 1.2 |
| Ovary | 11.7 | 10.6 | 10.2 | 12.0 | 9.6 | 327 | 10.8 |
| Vagina | 1.6 | 0.8 | 1.5 | 1.5 | - | 36 | 1.2 |
| Vulva | 2.1 | 1.4 | 1.4 | 1.5 | 1.7 | 51 | 1.6 |
| Urinary System | 17.6 | 21.3 | 18.6 | 21.3 | 15.8 | 547 | 18.9 |
| Urinary Bladder (Including in situ) | 7.7 | 10.9 | 6.8 | 10.1 | 6.6 | 233 | 8.4 |
| Kidney and Renal Pelvis | 9.2 | 9.8 | 10.9 | 10.5 | 8.7 | 295 | 9.8 |
| Ureter | - | - | - | - | - | 9 | 0.4 |
| Eye and Orbit | - | - | - | - | - | - | - |
| Brain and Other Nervous System | 2.6 | 4.0 | 2.3 | 3.6 | 3.1 | 100 | 3.1 |
| Brain | 2.2 | 2.6 | 1.9 | 2.6 | 2.3 | 74 | 2.3 |
| Endocrine System | 12.0 | 10.6 | 10.7 | 11.9 | 12.1 | 372 | 11.5 |
| Thyroid | 10.8 | 9.7 | 10.0 | 11.2 | 11.0 | 342 | 10.5 |
| Lymphomas | 15.5 | 17.6 | 16.6 | 13.2 | 14.1 | 480 | 15.4 |
| Hodgkin Lymphoma | 2.9 | 2.7 | 2.9 | 1.9 | 1.7 | 81 | 2.4 |
| Non-Hodgkin Lymphoma | 12.6 | 14.9 | 13.7 | 11.3 | 12.4 | 399 | 13.0 |
| Myelomas | 9.0 | 12.0 | 12.5 | 10.5 | 8.8 | 302 | 10.6 |
| Leukemias | 7.6 | 8.3 | 7.7 | 9.3 | 6.3 | 238 | 7.8 |
| Lymphocytic Leukemia | 2.5 | 3.5 | 2.5 | 4.0 | 1.9 | 88 | 2.9 |
| Acute Lymphocytic Leukemia | - | 1.2 | 1.1 | 1.4 | 0.7 | 33 | 1.0 |
| Chronic Lymphocytic Leukemia | 2.0 | 2.2 | 1.3 | 2.5 | 1.2 | 52 | 1.8 |
| Myeloid and Monocytic Leukemia | 4.2 | 4.5 | 3.6 | 4.8 | 4.0 | 129 | 4.2 |
| Acute Myeloid Leukemia | 2.9 | 3.6 | 2.2 | 3.3 | 2.6 | 88 | 2.9 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 1.0 | 0.8 | 1.4 | 1.3 | 1.2 | 37 | 1.2 |
| Other Leukemia | 0.9 | - | 1.6 | - | - | 21 | 0.7 |
| Mesothelioma | - | - | - | - | - | 11 | 0.4 |
| Kaposi Sarcoma | - | - | - | - | - | 8 | 0.2 |
| Ill-Defined & Unspecified Sites | 10.8 | 11.7 | 10.9 | 11.0 | 11.1 | 316 | 11.1 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females
 2003-2007 Combined**

| Cancer Site | Male Rate | Male Cases | Female Rate | Female Cases |
|--|-----------|------------|-------------|--------------|
| All Sites | 477.0 | 8,269 | 351.0 | 8,244 |
| Oral Cavity and Pharynx | 12.6 | 241 | 4.3 | 97 |
| Lip | 0.8 | 13 | 0.3 | 5 |
| Tongue | 3.6 | 66 | 1.0 | 24 |
| Salivary Gland | 0.9 | 20 | 0.7 | 17 |
| Floor of Mouth | 0.3 | 9 | 0.4 | 8 |
| Gum and Other Mouth | 1.5 | 29 | 1.0 | 20 |
| Nasopharynx | 1.0 | 19 | 0.3 | 8 |
| Tonsil | 1.7 | 39 | 0.4 | 9 |
| Oropharynx | 1.1 | 20 | - | - |
| Hypopharynx | 1.2 | 18 | - | - |
| Digestive System | 110.1 | 1,899 | 75.7 | 1,577 |
| Esophagus | 5.4 | 96 | 2.0 | 37 |
| Stomach | 16.4 | 287 | 10.2 | 213 |
| Small Intestine | 2.4 | 44 | 1.4 | 31 |
| Colon and Rectum | 55.0 | 934 | 38.5 | 815 |
| Colon excluding Rectum | 38.2 | 625 | 29.2 | 599 |
| Rectum and Rectosigmoid Junction | 16.8 | 309 | 9.3 | 216 |
| Anus, Anal Canal and Anorectum | 0.8 | 21 | 1.9 | 43 |
| Liver and Intrahepatic Bile Duct | 12.9 | 242 | 5.3 | 108 |
| Liver | 12.4 | 232 | 4.3 | 87 |
| Intrahepatic Bile Duct | 0.5 | 10 | 1.0 | 21 |
| Gallbladder | 0.8 | 17 | 3.0 | 58 |
| Pancreas | 12.7 | 203 | 10.5 | 210 |
| Respiratory System | 61.4 | 951 | 32.6 | 668 |
| Larynx | 6.6 | 116 | 0.9 | 19 |
| Lung and Bronchus | 53.1 | 802 | 31.1 | 632 |
| Bones and Joints | 0.9 | 31 | 1.4 | 42 |
| Soft Tissue (Including Heart) | 2.5 | 61 | 2.7 | 78 |
| Skin (Excluding Basal and Squamous) | 5.7 | 112 | 5.9 | 145 |
| Melanoma of the Skin | 4.7 | 88 | 4.9 | 120 |
| Breast (Invasive) | 1.1 | 19 | 94.6 | 2,342 |
| In situ (not included in All Sites) | - | - | 24.2 | 613 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males and Females
2003-2007 Combined**

| Cancer Site | Male Rate | Male Cases | Female Rate | Female Cases |
|--|-----------|------------|-------------|--------------|
| Female Genital System | * | * | 50.6 | 1,264 |
| Cervix Uteri | * | * | 14.8 | 415 |
| Corpus and Uterus, NOS | * | * | 21.1 | 502 |
| Corpus Uteri | * | * | 20.1 | 478 |
| Uterus, NOS | * | * | 1.0 | 24 |
| Ovary | * | * | 10.7 | 262 |
| Vagina | * | * | 1.0 | 21 |
| Vulva | * | * | 2.0 | 42 |
| Male Genital System | 164.3 | 2,753 | * | * |
| Prostate | 158.7 | 2,566 | * | * |
| Testis | 3.8 | 150 | * | * |
| Penis | 1.8 | 36 | * | * |
| Urinary System | 47.0 | 728 | 15.2 | 334 |
| Urinary Bladder (Including in situ) | 30.7 | 419 | 6.6 | 136 |
| Kidney and Renal Pelvis | 15.0 | 294 | 8.3 | 191 |
| Ureter | 0.6 | 7 | - | - |
| Eye and Orbit | 0.6 | 15 | 0.5 | 13 |
| Brain and Other Nervous System | 7.8 | 191 | 5.3 | 143 |
| Brain | 7.5 | 183 | 5.0 | 133 |
| Endocrine System | 4.8 | 128 | 18.1 | 530 |
| Thyroid | 4.2 | 112 | 17.6 | 518 |
| Lymphomas | 24.3 | 526 | 19.9 | 476 |
| Hodgkin Lymphoma | 3.6 | 101 | 2.7 | 84 |
| Non-Hodgkin Lymphoma | 20.7 | 425 | 17.2 | 392 |
| Myelomas | 7.2 | 125 | 5.5 | 117 |
| Leukemias | 12.4 | 265 | 8.7 | 220 |
| Lymphocytic Leukemia | 5.4 | 124 | 3.7 | 100 |
| Acute Lymphocytic Leukemia | 2.1 | 73 | 1.9 | 63 |
| Chronic Lymphocytic Leukemia | 2.9 | 43 | 1.6 | 32 |
| Myeloid and Monocytic Leukemia | 6.1 | 124 | 4.5 | 109 |
| Acute Myeloid Leukemia | 4.0 | 74 | 2.8 | 66 |
| Acute Monocytic Leukemia | 0.2 | 6 | - | - |
| Chronic Myeloid Leukemia | 1.8 | 42 | 1.5 | 37 |
| Other Leukemia | 0.9 | 17 | 0.5 | 11 |
| Mesothelioma | 1.3 | 18 | 0.5 | 11 |
| Kaposi Sarcoma | 1.9 | 41 | 0.4 | 8 |
| Ill-Defined & Unspecified Sites | 11.0 | 165 | 9.0 | 179 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2004-2007

| | Site Group | Rates | | | | Cases | Rates |
|---------------|------------------------------|-------|-------------|-------------|-----------------|-------------|--------------|
| | | 2004 | 2005 | 2006 | 2007 Prelim. | 2004-2007 | |
| Total | Brain | 0.8 | 1.2 | 1.3 | 1.1 | 395 | 1.1 |
| | Intracranial Meninges | 5.3 | 5.5 | 5.2 | 4.8 | 1,943 | 5.2 |
| | Cranial Nerves and other CNS | 1.3 | 1.4 | 1.2 | 1.1 | 459 | 1.2 |
| | Tumors of the Sellar Region | 2.1 | 2.5 | 2.5 | 2.1 | 820 | 2.3 |
| | Spinal Cord | 0.4 | 0.6 | 0.7 | 0.4 | 196 | 0.5 |
| | Spinal Meninges | 0.5 | 0.4 | 0.4 | 0.3 | 142 | 0.4 |
| | Total | | 10.5 | 11.5 | 11.4 | 9.8 | 3,955 |
| Male | Brain | 0.8 | 1.2 | 1.3 | 1.3 | 188 | 1.1 |
| | Intracranial Meninges | 3.3 | 3.6 | 3.4 | 3.2 | 545 | 3.4 |
| | Cranial Nerves and other CNS | 1.3 | 1.3 | 1.3 | 1.0 | 213 | 1.2 |
| | Tumors of the Sellar Region | 2.1 | 2.5 | 2.6 | 2.1 | 394 | 2.3 |
| | Spinal Cord | 0.5 | 0.5 | 0.6 | 0.7 | 99 | 0.6 |
| | Spinal Meninges | 0.3 | 0.2 | 0.2 | - | 32 | 0.2 |
| | Total | | 8.3 | 9.2 | 9.5 | 8.3 | 1,471 |
| Female | Brain | 0.9 | 1.2 | 1.3 | 1.0 | 207 | 1.1 |
| | Intracranial Meninges | 7.0 | 7.1 | 6.8 | 6.1 | 1,398 | 6.7 |
| | Cranial Nerves and other CNS | 1.2 | 1.4 | 1.2 | 1.3 | 246 | 1.3 |
| | Tumors of the Sellar Region | 2.2 | 2.6 | 2.5 | 2.1 | 426 | 2.3 |
| | Spinal Cord | 0.4 | 0.7 | 0.8 | 0.2 | 97 | 0.5 |
| | Spinal Meninges | 0.6 | 0.5 | 0.6 | 0.4 | 110 | 0.5 |
| | Total | | 12.3 | 13.6 | 13.1 | 11.1 | 2,484 |
| White | Brain | 0.9 | 1.3 | 1.2 | 1.1 | 320 | 1.1 |
| | Intracranial Meninges | 5.3 | 5.4 | 5.2 | 4.6 | 1,583 | 5.1 |
| | Cranial Nerves and other CNS | 1.4 | 1.4 | 1.4 | 1.2 | 392 | 1.3 |
| | Tumors of the Sellar Region | 1.9 | 2.0 | 2.2 | 2 | 577 | 2.0 |
| | Spinal Cord | 0.5 | 0.6 | 0.7 | 0.5 | 164 | 0.6 |
| | Spinal Meninges | 0.5 | 0.4 | 0.4 | 0.3 | 123 | 0.4 |
| | Total | | 10.3 | 11.2 | 11.2 | 9.6 | 3,159 |
| Black | Brain | 0.5 | 1.0 | 1.4 | 0.4 | 40 | 0.8 |
| | Intracranial Meninges | 6.1 | 5.1 | 5.5 | 5.3 | 230 | 5.5 |
| | Cranial Nerves and other CNS | 0.5 | - | - | - | 15 | 0.3 |
| | Tumors of the Sellar Region | 3.4 | 5.3 | 3.9 | 2.6 | 172 | 3.8 |
| | Spinal Cord | - | 0.4 | 0.4 | - | 14 | 0.3 |
| | Spinal Meninges | - | - | - | - | 9 | 0.2 |
| | Total | | 10.9 | 12.2 | 11.5 | 9.1 | 480 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 9. Comparative Incidence Rates, New Jersey and U.S., 2002-2006
Males**

| Cancer Site | New Jersey 2002-2006 | | | United States 2002-2006 | | |
|-----------------------------|----------------------|-------|-------|-------------------------|-------|-------|
| | All Races Combined | White | Black | All Races Combined | White | Black |
| Population: | | | | | | |
| All Sites | 603.9 | 600.5 | 647.5 | 556.5 | 550.1 | 626.0 |
| Colorectal | 65.3 | 65.3 | 70.7 | 59.0 | 58.2 | 68.4 |
| Lung | 79.6 | 79.7 | 92.5 | 86.4 | 85.9 | 104.8 |
| Prostate | 177.9 | 165.4 | 257.7 | 155.5 | 146.3 | 231.9 |
| Melanoma | 26.2 | 29.8 | 1.1 | 22.6 | 24.9 | 1.1 |
| Thyroid | 6.4 | 6.8 | 3.3 | 4.9 | 5.1 | 2.6 |
| Non-Hodgkin Lymphoma | 25.6 | 26.3 | 19.2 | 23.1 | 23.7 | 16.8 |

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 10. Comparative Incidence Rates, New Jersey and U.S., 2002-2006
Females**

| Cancer Site | New Jersey 2002-2006 | | | United States 2002-2006 | | |
|-----------------------------------|----------------------|-------|-------|-------------------------|-------|-------|
| | All Races Combined | White | Black | All Races Combined | White | Black |
| Population: | | | | | | |
| All Sites | 449.5 | 462.4 | 403.8 | 414.8 | 420.0 | 389.5 |
| Colorectal | 58.0 | 47.4 | 53.2 | 43.6 | 42.6 | 51.7 |
| Lung | 56.0 | 58.2 | 52.0 | 55.5 | 57.1 | 50.7 |
| Breast (invasive) | 128.0 | 132.6 | 108.8 | 121.8 | 123.5 | 113.0 |
| Endometrial (Corpus Uteri) | 27.6 | 29.0 | 21.2 | 22.9 | 23.5 | 19.4 |
| Melanoma | 16.8 | 19.8 | 1.2 | 14.6 | 16.5 | 1.0 |
| Thyroid | 18.8 | 20.3 | 9.9 | 14.2 | 14.8 | 8.7 |
| Non-Hodgkin Lymphoma | 17.7 | 18.4 | 12.9 | 16.3 | 16.8 | 11.4 |

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 11. Age-adjusted Mortality Rates, Males All Races Combined

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 236.7 | 222.3 | 222.0 | 215.6 | 33,954 | 224.1 |
| Oral Cavity and Pharynx | 4.0 | 3.5 | 3.5 | 3.4 | 581 | 3.6 |
| Lip | - | - | - | 0.0 | - | - |
| Tongue | 1.2 | 1.2 | 1.0 | 0.9 | 175 | 1.1 |
| Salivary Gland | 0.4 | 0.2 | 0.3 | 0.4 | 48 | 0.3 |
| Floor of Mouth | - | - | - | - | 9 | 0.1 |
| Gum and Other Mouth | 0.5 | 0.4 | 0.3 | 0.3 | 62 | 0.4 |
| Nasopharynx | 0.4 | 0.3 | 0.3 | 0.3 | 55 | 0.3 |
| Tonsil | 0.2 | 0.2 | 0.3 | 0.2 | 40 | 0.2 |
| Oropharynx | 0.4 | 0.3 | 0.4 | 0.4 | 64 | 0.4 |
| Hypopharynx | 0.1 | - | 0.1 | - | 18 | 0.1 |
| Digestive System | 64.0 | 59.0 | 59.3 | 58.7 | 9,245 | 60.2 |
| Esophagus | 7.4 | 7.0 | 8.0 | 7.8 | 1,198 | 7.5 |
| Stomach | 7.3 | 6.9 | 6.3 | 5.7 | 1,000 | 6.5 |
| Small Intestine | 0.6 | 0.3 | 0.4 | 0.5 | 73 | 0.5 |
| Colon and Rectum | 26.0 | 23.1 | 22.6 | 22.4 | 3,526 | 23.5 |
| Colon excluding Rectum | 22.1 | 19.4 | 18.5 | 18.7 | 2,933 | 19.7 |
| Rectum and Rectosigmoid Junction | 3.9 | 3.7 | 4.1 | 3.6 | 593 | 3.8 |
| Anus, Anal Canal and Anorectum | 0.1 | 0.1 | 0.1 | 0.1 | 21 | 0.1 |
| Liver and Intrahepatic Bile Duct | 7.8 | 7.2 | 8.0 | 7.7 | 1,221 | 7.7 |
| Liver | 6.4 | 6.0 | 6.5 | 6.1 | 1,001 | 6.3 |
| Intrahepatic Bile Duct | 1.4 | 1.2 | 1.5 | 1.6 | 220 | 1.4 |
| Gallbladder | 0.7 | 0.7 | 0.5 | 0.5 | 90 | 0.6 |
| Pancreas | 12.8 | 12.9 | 12.3 | 12.9 | 1,957 | 12.7 |
| Respiratory System | 69.3 | 64.6 | 64.8 | 61.8 | 9,980 | 65.1 |
| Larynx | 2.5 | 2.6 | 2.4 | 2.5 | 390 | 2.5 |
| Lung and Bronchus | 66.2 | 61.5 | 61.7 | 59.1 | 9,507 | 62.1 |
| Bones and Joints | 0.3 | 0.4 | 0.3 | 0.6 | 67 | 0.4 |
| Soft Tissue (Including Heart) | 1.4 | 1.2 | 1.6 | 1.8 | 234 | 1.5 |
| Skin (Excluding Basal and Squamous) | 4.7 | 5.3 | 5.4 | 5.5 | 802 | 5.2 |
| Melanoma of the Skin | 3.7 | 3.9 | 4.1 | 4.0 | 613 | 3.9 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11 (continued). Age-adjusted Mortality Rates, Males All Races Combined

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Breast | 0.4 | 0.7 | 0.7 | 0.4 | 83 | 0.6 |
| Male Genital System | 27.5 | 24.8 | 24.2 | 21.5 | 3,425 | 24.4 |
| Prostate | 26.9 | 24.3 | 23.9 | 21.2 | 3,360 | 24.0 |
| Testis | 0.3 | 0.2 | 0.1 | 0.1 | 32 | 0.2 |
| Penis | 0.2 | 0.2 | 0.2 | 0.1 | 29 | 0.2 |
| Urinary System | 13.7 | 13.9 | 14.3 | 14.3 | 2,085 | 14.1 |
| Urinary Bladder | 7.4 | 8.5 | 8.8 | 8.8 | 1,211 | 8.4 |
| Kidney and Renal Pelvis | 5.9 | 5.2 | 5.3 | 5.1 | 826 | 5.3 |
| Ureter | - | 0.2 | - | 0.2 | 19 | 0.1 |
| Eye | - | - | - | - | 10 | 0.1 |
| Brain and Other Nervous System | 4.6 | 4.6 | 4.7 | 4.3 | 743 | 4.6 |
| Endocrine System | 0.8 | 1.0 | 0.6 | 0.7 | 120 | 0.8 |
| Thyroid | 0.5 | 0.7 | 0.3 | 0.5 | 72 | 0.5 |
| Lymphomas | 10.7 | 10.2 | 9.0 | 9.3 | 1,496 | 9.8 |
| Hodgkin Lymphoma | 0.5 | 0.7 | 0.5 | 0.5 | 92 | 0.6 |
| Non-Hodgkin Lymphoma | 10.2 | 9.5 | 8.5 | 8.8 | 1,404 | 9.2 |
| Multiple Myeloma | 4.8 | 3.7 | 4.2 | 4.5 | 651 | 4.3 |
| Leukemias | 10.1 | 9.7 | 9.3 | 9.2 | 1,437 | 9.6 |
| Lymphocytic Leukemia | 3.2 | 2.6 | 2.8 | 2.8 | 424 | 2.8 |
| Acute Lymphocytic Leukemia | 0.6 | 0.5 | 0.5 | 0.7 | 95 | 0.6 |
| Chronic Lymphocytic Leukemia | 2.3 | 2.0 | 2.2 | 1.9 | 306 | 2.1 |
| Myeloid and Monocytic Leukemia | 4.3 | 4.5 | 4.0 | 3.9 | 633 | 4.2 |
| Acute Myeloid Leukemia | 3.7 | 3.8 | 3.6 | 3.2 | 541 | 3.6 |
| Acute Monocytic Leukemia | - | - | 0.0 | - | 9 | 0.1 |
| Chronic Myeloid Leukemia | 0.5 | 0.4 | 0.2 | 0.4 | 55 | 0.4 |
| Other Leukemia | 2.6 | 2.7 | 2.5 | 2.5 | 380 | 2.6 |
| Ill-Defined & Unspecified Sites | 20.2 | 19.5 | 20.2 | 19.4 | 2,995 | 19.8 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12. Age-adjusted Mortality Rates, Females All Races Combined

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 171.3 | 164.3 | 160.5 | 162.2 | 35,560 | 164.6 |
| Oral Cavity and Pharynx | 1.4 | 1.4 | 1.3 | 1.4 | 303 | 1.4 |
| Lip | 0.0 | - | - | - | - | - |
| Tongue | 0.4 | 0.4 | 0.4 | 0.5 | 91 | 0.4 |
| Salivary Gland | 0.1 | 0.1 | 0.1 | 0.1 | 27 | 0.1 |
| Floor of Mouth | - | 0.0 | - | - | 7 | 0.0 |
| Gum and Other Mouth | 0.3 | 0.2 | 0.1 | 0.2 | 47 | 0.2 |
| Nasopharynx | 0.1 | 0.1 | - | 0.2 | 26 | 0.1 |
| Tonsil | - | 0.1 | - | 0.1 | 18 | 0.1 |
| Oropharynx | 0.1 | 0.1 | 0.2 | 0.2 | 30 | 0.1 |
| Hypopharynx | - | - | - | - | 8 | 0.0 |
| Digestive System | 39.7 | 38.0 | 36.3 | 37.2 | 8,390 | 37.8 |
| Esophagus | 1.8 | 1.9 | 1.8 | 1.8 | 393 | 1.8 |
| Stomach | 3.4 | 3.3 | 3.7 | 3.3 | 751 | 3.4 |
| Small Intestine | 0.3 | 0.2 | 0.3 | 0.2 | 62 | 0.3 |
| Colon and Rectum | 19.2 | 16.4 | 16.3 | 16.0 | 3,832 | 17.0 |
| Colon excluding Rectum | 16.7 | 14.2 | 14.1 | 13.6 | 3,313 | 14.7 |
| Rectum and Rectosigmoid Junction | 2.5 | 2.2 | 2.2 | 2.4 | 519 | 2.3 |
| Anus, Anal Canal and Anorectum | 0.3 | 0.3 | 0.1 | 0.1 | 43 | 0.2 |
| Liver and Intrahepatic Bile Duct | 3.0 | 3.5 | 2.8 | 3.2 | 686 | 3.1 |
| Liver | 2.0 | 2.4 | 1.9 | 1.9 | 445 | 2.0 |
| Intrahepatic Bile Duct | 1.1 | 1.1 | 0.9 | 1.3 | 241 | 1.1 |
| Gallbladder | 1.0 | 1.1 | 0.9 | 1.0 | 217 | 1.0 |
| Pancreas | 9.7 | 10.2 | 9.3 | 10.3 | 2,160 | 9.9 |
| Respiratory System | 41.5 | 40.9 | 39.8 | 39.8 | 8,621 | 40.5 |
| Larynx | 0.4 | 0.4 | 0.6 | 0.5 | 102 | 0.5 |
| Lung and Bronchus | 41.0 | 40.3 | 39.0 | 39.1 | 8,483 | 39.9 |
| Bones and Joints | 0.3 | 0.4 | 0.2 | 0.3 | 58 | 0.3 |
| Soft Tissue (Including Heart) | 1.1 | 1.1 | 1.6 | 1.1 | 259 | 1.3 |
| Skin (Excluding Basal and Squamous) | 2.0 | 2.2 | 2.3 | 2.0 | 460 | 2.1 |
| Melanoma of the Skin | 1.7 | 1.8 | 1.9 | 1.7 | 369 | 1.8 |
| Breast | 28.7 | 26.0 | 26.9 | 27.0 | 5,770 | 27.2 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12 (continued). Age-adjusted Mortality Rates, Females All Races Combined

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Female Genital System | 18.5 | 16.9 | 16.6 | 18.6 | 3,739 | 17.7 |
| Cervix Uteri | 2.7 | 2.6 | 2.6 | 2.9 | 547 | 2.7 |
| Corpus and Uterus, NOS | 5.0 | 5.0 | 5.0 | 5.5 | 1,104 | 5.1 |
| Corpus Uteri | 2.1 | 2.3 | 1.9 | 2.2 | 454 | 2.1 |
| Uterus, NOS | 2.9 | 2.7 | 3.1 | 3.3 | 650 | 3.0 |
| Ovary | 9.8 | 8.6 | 8.4 | 9.3 | 1,913 | 9.0 |
| Vagina | 0.2 | 0.2 | 0.2 | 0.2 | 47 | 0.2 |
| Vulva | 0.4 | 0.4 | 0.4 | 0.5 | 94 | 0.4 |
| Urinary System | 5.6 | 5.2 | 5.1 | 5.2 | 1,190 | 5.3 |
| Urinary Bladder | 2.6 | 2.7 | 2.5 | 2.8 | 607 | 2.6 |
| Kidney and Renal Pelvis | 2.8 | 2.3 | 2.5 | 2.3 | 541 | 2.5 |
| Ureter | 0.2 | 0.1 | 0.1 | 0.1 | 28 | 0.1 |
| Eye | 0.1 | - | - | - | 10 | 0.0 |
| Brain and Other Nervous System | 2.5 | 3.3 | 3.0 | 2.9 | 600 | 2.9 |
| Endocrine System | 0.8 | 1.1 | 0.8 | 0.9 | 188 | 0.9 |
| Thyroid | 0.5 | 0.7 | 0.5 | 0.6 | 130 | 0.6 |
| Lymphomas | 6.2 | 6.3 | 5.8 | 6.3 | 1,351 | 6.2 |
| Hodgkin Lymphoma | 0.5 | 0.4 | 0.4 | 0.5 | 87 | 0.4 |
| Non-Hodgkin Lymphoma | 5.7 | 5.9 | 5.5 | 5.8 | 1,264 | 5.7 |
| Multiple Myeloma | 3.4 | 2.9 | 2.9 | 2.9 | 653 | 3.0 |
| Leukemias | 5.7 | 5.8 | 5.0 | 5.0 | 1,175 | 5.4 |
| Lymphocytic Leukemia | 1.6 | 1.3 | 1.5 | 1.1 | 304 | 1.4 |
| Acute Lymphocytic Leukemia | 0.4 | 0.4 | 0.5 | 0.4 | 80 | 0.4 |
| Chronic Lymphocytic Leukemia | 1.1 | 0.8 | 1.0 | 0.6 | 209 | 0.9 |
| Myeloid and Monocytic Leukemia | 2.7 | 2.8 | 2.2 | 2.2 | 525 | 2.5 |
| Acute Myeloid Leukemia | 2.4 | 2.4 | 1.8 | 1.9 | 449 | 2.1 |
| Acute Monocytic Leukemia | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.2 | 0.2 | 0.3 | 0.2 | 49 | 0.2 |
| Other Leukemia | 1.5 | 1.8 | 1.3 | 1.7 | 346 | 1.5 |
| Ill-Defined & Unspecified Sites | 13.7 | 12.7 | 12.7 | 11.4 | 2,793 | 12.6 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13. Age-adjusted Mortality Rates, White Males

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 235.0 | 220.5 | 222.8 | 218.4 | 29,212 | 224.2 |
| Oral Cavity and Pharynx | 3.9 | 3.4 | 2.9 | 3.4 | 462 | 3.4 |
| Lip | 0.0 | - | - | - | - | - |
| Tongue | 1.3 | 1.2 | 0.9 | 0.9 | 148 | 1.1 |
| Salivary Gland | 0.4 | 0.3 | 0.3 | 0.4 | 44 | 0.3 |
| Floor of Mouth | 0.0 | - | - | - | 5 | 0.0 |
| Gum and Other Mouth | 0.4 | 0.4 | 0.3 | 0.3 | 48 | 0.4 |
| Nasopharynx | 0.4 | 0.3 | 0.2 | 0.2 | 37 | 0.3 |
| Tonsil | 0.3 | 0.2 | 0.2 | 0.3 | 33 | 0.2 |
| Oropharynx | 0.4 | 0.3 | 0.4 | 0.4 | 50 | 0.4 |
| Hypopharynx | - | - | - | - | 11 | 0.1 |
| Digestive System | 63.1 | 57.5 | 58.8 | 58.8 | 7,831 | 59.6 |
| Esophagus | 7.3 | 7.1 | 8.1 | 7.5 | 1,013 | 7.5 |
| Stomach | 6.8 | 6.3 | 6.0 | 5.5 | 806 | 6.1 |
| Small Intestine | 0.5 | 0.3 | 0.5 | 0.5 | 59 | 0.4 |
| Colon and Rectum | 26.1 | 22.9 | 22.3 | 22.8 | 3,040 | 23.5 |
| Colon excluding Rectum | 22.2 | 19.3 | 18.1 | 19.1 | 2,535 | 19.7 |
| Rectum and Rectosigmoid Junction | 3.9 | 3.6 | 4.1 | 3.7 | 505 | 3.8 |
| Anus, Anal Canal and Anorectum | - | - | 0.1 | - | 15 | 0.1 |
| Liver and Intrahepatic Bile Duct | 7.2 | 6.5 | 7.5 | 7.6 | 966 | 7.2 |
| Liver | 5.8 | 5.2 | 5.9 | 5.9 | 767 | 5.7 |
| Intrahepatic Bile Duct | 1.5 | 1.3 | 1.5 | 1.7 | 199 | 1.5 |
| Gallbladder | 0.7 | 0.7 | 0.5 | 0.5 | 78 | 0.6 |
| Pancreas | 12.9 | 12.8 | 12.8 | 13.3 | 1,711 | 13.0 |
| Respiratory System | 68.7 | 64.3 | 65.3 | 62.7 | 8,584 | 65.2 |
| Larynx | 2.2 | 2.4 | 2.0 | 2.1 | 293 | 2.2 |
| Lung and Bronchus | 65.9 | 61.2 | 62.6 | 60.2 | 8,217 | 62.5 |
| Bones and Joints | 0.4 | 0.5 | 0.3 | 0.7 | 58 | 0.4 |
| Soft Tissue (Including Heart) | 1.5 | 1.1 | 1.6 | 2.0 | 204 | 1.5 |
| Skin (Excluding Basal and Squamous) | 5.3 | 6.0 | 6.2 | 6.3 | 781 | 5.9 |
| Melanoma of the Skin | 4.2 | 4.5 | 4.8 | 4.6 | 602 | 4.5 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13 (continued). Age-adjusted Mortality Rates, White Males

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Breast | 0.4 | 0.7 | 0.7 | 0.4 | 68 | 0.5 |
| Male Genital System | 25.3 | 22.4 | 22.5 | 19.8 | 2,770 | 22.5 |
| Prostate | 24.8 | 21.9 | 22.1 | 19.5 | 2,712 | 22.0 |
| Testis | 0.3 | 0.3 | 0.2 | - | 29 | 0.2 |
| Penis | 0.2 | 0.2 | 0.2 | 0.2 | 26 | 0.2 |
| Urinary System | 14.4 | 14.8 | 15.1 | 15.2 | 1,910 | 14.9 |
| Urinary Bladder | 8.0 | 8.9 | 9.5 | 9.4 | 1,132 | 8.9 |
| Kidney and Renal Pelvis | 5.9 | 5.6 | 5.4 | 5.2 | 731 | 5.5 |
| Ureter | - | 0.2 | - | 0.2 | 19 | 0.1 |
| Eye | - | - | - | - | 10 | 0.1 |
| Brain and Other Nervous System | 5.1 | 5.2 | 5.1 | 4.8 | 685 | 5.1 |
| Endocrine System | 0.8 | 1.1 | 0.6 | 0.7 | 106 | 0.8 |
| Thyroid | 0.5 | 0.7 | 0.3 | 0.5 | 67 | 0.5 |
| Lymphomas | 11.3 | 10.5 | 9.3 | 9.8 | 1,335 | 10.2 |
| Hodgkin Lymphoma | 0.6 | 0.7 | 0.5 | 0.5 | 77 | 0.6 |
| Non-Hodgkin Lymphoma | 10.7 | 9.9 | 8.8 | 9.2 | 1,258 | 9.6 |
| Multiple Myeloma | 4.3 | 3.5 | 4.1 | 4.5 | 531 | 4.1 |
| Leukemias | 10.5 | 10.1 | 9.8 | 9.7 | 1,291 | 10.0 |
| Lymphocytic Leukemia | 3.4 | 2.6 | 3.0 | 2.9 | 377 | 3.0 |
| Acute Lymphocytic Leukemia | 0.6 | 0.5 | 0.5 | 0.7 | 74 | 0.6 |
| Chronic Lymphocytic Leukemia | 2.5 | 2.1 | 2.3 | 2.0 | 282 | 2.2 |
| Myeloid and Monocytic Leukemia | 4.4 | 4.6 | 4.3 | 4.2 | 570 | 4.4 |
| Acute Myeloid Leukemia | 3.7 | 4.0 | 3.9 | 3.5 | 492 | 3.8 |
| Acute Monocytic Leukemia | - | - | - | - | 8 | 0.1 |
| Chronic Myeloid Leukemia | 0.5 | 0.4 | 0.2 | 0.4 | 45 | 0.3 |
| Other Leukemia | 2.7 | 2.8 | 2.6 | 2.7 | 344 | 2.7 |
| Ill-Defined and Unspecified Sites | 20.0 | 19.6 | 20.4 | 19.7 | 2,586 | 19.9 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14. Age-adjusted Mortality Rates, White Females

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 172.2 | 165.8 | 161.8 | 162.9 | 30,616 | 165.7 |
| Oral Cavity and Pharynx | 1.2 | 1.3 | 1.3 | 1.4 | 242 | 1.3 |
| Lip | 0.0 | - | - | - | - | - |
| Tongue | 0.3 | 0.4 | 0.4 | 0.4 | 75 | 0.4 |
| Salivary Gland | - | 0.2 | - | - | 20 | 0.1 |
| Floor of Mouth | - | - | - | - | - | - |
| Gum and Other Mouth | 0.3 | 0.2 | 0.1 | 0.1 | 41 | 0.2 |
| Nasopharynx | - | - | - | 0.2 | 17 | 0.1 |
| Tonsil | - | 0.1 | - | 0.1 | 16 | 0.1 |
| Oropharynx | 0.1 | - | 0.2 | 0.1 | 22 | 0.1 |
| Hypopharynx | - | - | - | - | 7 | 0.0 |
| Digestive System | 39.0 | 37.6 | 35.6 | 36.3 | 7,137 | 37.1 |
| Esophagus | 1.8 | 1.9 | 1.7 | 1.7 | 334 | 1.8 |
| Stomach | 3.1 | 3.0 | 3.3 | 2.8 | 583 | 3.1 |
| Small Intestine | 0.4 | 0.3 | 0.3 | 0.2 | 54 | 0.3 |
| Colon and Rectum | 18.7 | 16.4 | 16.0 | 15.6 | 3,278 | 16.7 |
| Colon excluding Rectum | 16.1 | 14.2 | 13.9 | 13.0 | 2,823 | 14.3 |
| Rectum and Rectosigmoid Junction | 2.5 | 2.3 | 2.1 | 2.6 | 455 | 2.4 |
| Anus, Anal Canal and Anorectum | 0.3 | 0.2 | 0.2 | 0.1 | 37 | 0.2 |
| Liver and Intrahepatic Bile Duct | 3.1 | 3.3 | 2.6 | 3.1 | 572 | 3.0 |
| Liver | 2.0 | 2.2 | 1.8 | 1.7 | 363 | 1.9 |
| Intrahepatic Bile Duct | 1.1 | 1.1 | 0.8 | 1.4 | 209 | 1.1 |
| Gallbladder | 1.0 | 1.0 | 0.9 | 1.0 | 185 | 1.0 |
| Pancreas | 9.6 | 10.1 | 9.5 | 10.5 | 1,872 | 9.9 |
| Respiratory System | 42.3 | 41.9 | 41.1 | 40.9 | 7,535 | 41.5 |
| Larynx | 0.3 | 0.4 | 0.6 | 0.6 | 81 | 0.4 |
| Lung and Bronchus | 41.9 | 41.3 | 40.4 | 40.1 | 7,425 | 40.9 |
| Bones and Joints | 0.3 | 0.3 | 0.2 | 0.3 | 49 | 0.3 |
| Soft Tissue (Including Heart) | 1.2 | 1.3 | 1.5 | 1.2 | 227 | 1.3 |
| Skin (Excluding Basal and Squamous) | 2.3 | 2.6 | 2.6 | 2.4 | 446 | 2.5 |
| Melanoma of the Skin | 2.0 | 2.1 | 2.2 | 2.0 | 361 | 2.1 |
| Breast | 28.6 | 25.7 | 26.9 | 26.9 | 4,854 | 27.0 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14 (continued). Age-adjusted Mortality Rates, White Females

| Cancer Site | Rates | | | | Cases 2003-2007 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Female Genital System | 18.3 | 17.0 | 16.8 | 18.0 | 3,149 | 17.6 |
| Cervix Uteri | 2.3 | 2.4 | 2.5 | 2.4 | 399 | 2.4 |
| Corpus and Uterus, NOS | 4.8 | 4.9 | 4.7 | 5.3 | 910 | 4.9 |
| Corpus Uteri | 2.1 | 2.3 | 2.1 | 2.3 | 397 | 2.2 |
| Uterus, NOS | 2.7 | 2.6 | 2.6 | 3.0 | 513 | 2.7 |
| Ovary | 10.3 | 9.2 | 8.9 | 9.4 | 1,691 | 9.4 |
| Vagina | 0.2 | 0.2 | 0.2 | 0.2 | 37 | 0.2 |
| Vulva | 0.5 | 0.4 | 0.4 | 0.5 | 87 | 0.4 |
| Urinary System | 5.9 | 5.3 | 5.2 | 5.1 | 1,049 | 5.4 |
| Urinary Bladder | 2.6 | 2.7 | 2.5 | 2.6 | 530 | 2.6 |
| Kidney and Renal Pelvis | 3.0 | 2.4 | 2.6 | 2.3 | 485 | 2.6 |
| Ureter | 0.2 | 0.1 | - | 0.1 | 24 | 0.1 |
| Eye | 0.1 | - | - | - | 9 | 0.0 |
| Brain and Other Nervous System | 2.8 | 3.6 | 3.4 | 3.4 | 556 | 3.3 |
| Endocrine System | 0.8 | 1.1 | 0.7 | 0.9 | 160 | 0.9 |
| Thyroid | 0.5 | 0.7 | 0.5 | 0.6 | 111 | 0.6 |
| Lymphomas | 6.5 | 6.7 | 6.1 | 6.7 | 1,226 | 6.5 |
| Hodgkin Lymphoma | 0.5 | 0.5 | 0.3 | 0.5 | 77 | 0.5 |
| Non-Hodgkin Lymphoma | 5.9 | 6.2 | 5.7 | 6.2 | 1,149 | 6.0 |
| Multiple Myeloma | 3.0 | 2.5 | 2.5 | 2.6 | 495 | 2.6 |
| Leukemias | 6.0 | 5.9 | 5.2 | 5.1 | 1,044 | 5.6 |
| Lymphocytic Leukemia | 1.7 | 1.4 | 1.6 | 1.1 | 281 | 1.5 |
| Acute Lymphocytic Leukemia | 0.5 | 0.5 | 0.5 | 0.4 | 70 | 0.5 |
| Chronic Lymphocytic Leukemia | 1.1 | 0.9 | 1.1 | 0.7 | 197 | 0.9 |
| Myeloid and Monocytic Leukemia | 2.9 | 2.9 | 2.2 | 2.3 | 467 | 2.6 |
| Acute Myeloid Leukemia | 2.6 | 2.5 | 1.8 | 2.0 | 402 | 2.2 |
| Acute Monocytic Leukemia | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.2 | 0.2 | 0.2 | 0.2 | 42 | 0.2 |
| Other Leukemia | 1.4 | 1.6 | 1.4 | 1.7 | 296 | 1.5 |
| Ill-Defined & Unspecified Sites | 13.9 | 12.9 | 12.6 | 11.6 | 2,438 | 12.8 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15. Age-adjusted Mortality Rates, Black Males

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 313.6 | 283.2 | 264.0 | 254.0 | 4,028 | 278.1 |
| Oral Cavity and Pharynx | 5.2 | 5.4 | 8.1 | 4.4 | 100 | 5.8 |
| Lip | - | - | - | - | - | - |
| Tongue | - | 1.5 | 1.9 | 1.4 | 24 | 1.3 |
| Salivary Gland | - | - | - | - | - | - |
| Floor of Mouth | - | - | - | - | - | - |
| Gum and Other Mouth | 1.6 | - | - | - | 11 | 0.6 |
| Nasopharynx | - | - | - | - | 11 | 0.6 |
| Tonsil | - | - | 1.1 | - | 7 | 0.4 |
| Oropharynx | - | - | - | - | 13 | 0.7 |
| Hypopharynx | - | - | - | - | 6 | 0.3 |
| Digestive System | 84.4 | 77.0 | 71.6 | 74.7 | 1,144 | 76.8 |
| Esophagus | 10.8 | 8.1 | 9.7 | 12.4 | 165 | 10.3 |
| Stomach | 11.3 | 11.1 | 8.0 | 9.0 | 137 | 9.9 |
| Small Intestine | 1.2 | - | - | - | 14 | 0.9 |
| Colon and Rectum | 32.9 | 28.7 | 32.0 | 27.1 | 421 | 30.1 |
| Colon excluding Rectum | 27.6 | 23.7 | 27.4 | 22.4 | 346 | 25.2 |
| Rectum and Rectosigmoid Junction | 5.3 | 5.1 | 4.5 | 4.7 | 75 | 4.9 |
| Anus, Anal Canal and Anorectum | - | - | - | - | 6 | 0.3 |
| Liver and Intrahepatic Bile Duct | 12.4 | 11.7 | 8.4 | 9.2 | 178 | 10.4 |
| Liver | 11.7 | 11.1 | 7.4 | 8.5 | 163 | 9.6 |
| Intrahepatic Bile Duct | - | - | 1.1 | - | 15 | 0.8 |
| Gallbladder | - | - | - | - | 6 | 0.4 |
| Pancreas | 15.0 | 15.9 | 11.2 | 13.9 | 205 | 14.0 |
| Respiratory System | 94.2 | 83.4 | 78.6 | 72.0 | 1,224 | 81.8 |
| Larynx | 5.9 | 5.0 | 6.2 | 6.1 | 90 | 5.8 |
| Lung and Bronchus | 87.1 | 78.4 | 71.7 | 65.9 | 1,127 | 75.6 |
| Bones and Joints | - | - | - | - | 9 | 0.5 |
| Soft Tissue (Including Heart) | 1.2 | 1.6 | 1.7 | - | 24 | 1.3 |
| Skin (Excluding Basal and Squamous) | - | 1.1 | - | - | 16 | 1.1 |
| Melanoma of the Skin | - | - | - | - | 7 | 0.5 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15 (continued). Age-adjusted Mortality Rates, Black Males

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Breast | - | - | 1.9 | - | 14 | 1.0 |
| Male Genital System | 61.4 | 54.8 | 48.2 | 46.7 | 614 | 52.6 |
| Prostate | 60.6 | 54.8 | 48.2 | 46.5 | 609 | 52.3 |
| Testis | - | - | - | - | - | - |
| Penis | - | - | - | - | - | - |
| Urinary System | 10.0 | 9.0 | 10.0 | 10.8 | 143 | 10.0 |
| Urinary Bladder | 2.6 | 6.1 | 4.3 | 6.2 | 63 | 4.8 |
| Kidney and Renal Pelvis | 7.1 | 2.9 | 5.7 | 4.6 | 79 | 5.1 |
| Ureter | - | - | - | - | - | - |
| Eye | - | - | - | - | - | - |
| Brain and Other Nervous System | 2.8 | 2.1 | 3.4 | 2.4 | 47 | 2.7 |
| Endocrine System | - | - | - | - | 8 | 0.4 |
| Thyroid | - | - | - | - | - | - |
| Lymphomas | 6.9 | 8.3 | 5.8 | 6.2 | 119 | 6.8 |
| Hodgkin Lymphoma | - | 0.9 | - | - | 11 | 0.5 |
| Non-Hodgkin Lymphoma | 6.5 | 7.4 | 5.5 | 5.6 | 108 | 6.3 |
| Multiple Myeloma | 10.7 | 7.5 | 5.8 | 6.7 | 111 | 7.6 |
| Leukemias | 8.6 | 7.7 | 7.1 | 5.9 | 114 | 7.3 |
| Lymphocytic Leukemia | 2.7 | 2.1 | 2.3 | 2.2 | 38 | 2.3 |
| Acute Lymphocytic Leukemia | - | - | - | 0.9 | 14 | 0.6 |
| Chronic Lymphocytic Leukemia | 1.6 | 1.9 | - | 1.3 | 22 | 1.5 |
| Myeloid and Monocytic Leukemia | 3.4 | 3.1 | 2.5 | 2.2 | 45 | 2.8 |
| Acute Myeloid Leukemia | 2.9 | 1.9 | 2.1 | 1.4 | 34 | 2.1 |
| Acute Monocytic Leukemia | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - | 8 | 0.5 |
| Other Leukemia | 2.5 | 2.4 | 2.3 | 1.5 | 31 | 2.2 |
| Ill-Defined & Unspecified Sites | 26.5 | 22.8 | 20.2 | 20.4 | 341 | 22.4 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16. Age-adjusted Mortality Rates, Black Females

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|-------|-------|-------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| All Sites | 193.7 | 180.8 | 181.6 | 187.6 | 4,269 | 185.9 |
| Oral Cavity and Pharynx | 2.8 | 2.4 | 1.5 | 2.0 | 51 | 2.2 |
| Lip | - | - | - | - | - | - |
| Tongue | - | - | - | - | 11 | 0.5 |
| Salivary Gland | - | - | - | - | 6 | 0.3 |
| Floor of Mouth | - | - | - | - | - | - |
| Gum and Other Mouth | - | - | - | - | 5 | 0.2 |
| Nasopharynx | - | - | - | - | 7 | 0.3 |
| Tonsil | - | - | - | - | - | - |
| Oropharynx | - | - | - | - | 7 | 0.3 |
| Hypopharynx | - | - | - | - | - | - |
| Digestive System | 50.6 | 44.3 | 47.9 | 49.2 | 1,070 | 48.0 |
| Esophagus | 2.3 | 1.7 | 2.2 | 2.7 | 52 | 2.2 |
| Stomach | 5.1 | 5.2 | 7.2 | 5.5 | 128 | 5.8 |
| Small Intestine | - | - | - | - | 8 | 0.4 |
| Colon and Rectum | 26.1 | 18.8 | 22.7 | 23.0 | 501 | 22.6 |
| Colon excluding Rectum | 23.9 | 16.5 | 19.4 | 20.9 | 447 | 20.2 |
| Rectum and Rectosigmoid Junction | 2.3 | 2.2 | 3.3 | 2.1 | 54 | 2.5 |
| Anus, Anal Canal and Anorectum | - | - | - | - | 6 | 0.3 |
| Liver and Intrahepatic Bile Duct | 2.3 | 3.1 | 4.4 | 4.9 | 86 | 3.7 |
| Liver | 1.9 | 2.7 | 2.6 | 3.2 | 61 | 2.6 |
| Intrahepatic Bile Duct | - | - | 1.8 | 1.7 | 25 | 1.1 |
| Gallbladder | 1.1 | 1.6 | 0.9 | 1.3 | 28 | 1.2 |
| Pancreas | 12.3 | 12.8 | 9.2 | 10.1 | 245 | 11.1 |
| Respiratory System | 42.6 | 44.5 | 41.5 | 41.9 | 975 | 42.6 |
| Larynx | 1.1 | 0.9 | 1.2 | - | 21 | 0.9 |
| Lung and Bronchus | 41.2 | 43.4 | 40.2 | 41.2 | 949 | 41.5 |
| Bones and Joints | - | 0.7 | - | - | 8 | 0.3 |
| Soft Tissue (Including Heart) | 1.3 | - | 2.3 | 1.0 | 31 | 1.3 |
| Skin (Excluding Basal and Squamous) | - | - | - | - | 9 | 0.4 |
| Melanoma of the Skin | - | - | - | - | - | - |
| Breast | 34.5 | 33.3 | 30.1 | 33.4 | 786 | 32.8 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16 (continued). Age-adjusted Mortality Rates, Black Females

| Cancer Site | Rates | | | | Cases 2003-2006 | Rates |
|--|-------|------|------|------|--------------------|-------|
| | 2003 | 2004 | 2005 | 2006 | | |
| Female Genital System | 23.4 | 19.9 | 18.0 | 25.0 | 510 | 21.6 |
| Cervix Uteri | 6.5 | 5.2 | 3.8 | 6.5 | 135 | 5.5 |
| Corpus and Uterus, NOS | 8.0 | 6.5 | 8.0 | 7.8 | 173 | 7.5 |
| Corpus Uteri | 3.2 | 2.9 | 1.0 | 2.0 | 51 | 2.3 |
| Uterus, NOS | 4.8 | 3.6 | 6.9 | 5.8 | 122 | 5.3 |
| Ovary | 7.6 | 7.2 | 5.7 | 9.5 | 178 | 7.5 |
| Vagina | - | - | - | - | 9 | 0.4 |
| Vulva | - | - | - | - | 6 | 0.2 |
| Urinary System | 4.7 | 5.3 | 4.9 | 7.6 | 123 | 5.6 |
| Urinary Bladder | 3.2 | 3.0 | 2.4 | 4.6 | 70 | 3.3 |
| Kidney and Renal Pelvis | 1.0 | 2.1 | 2.4 | 2.6 | 47 | 2.0 |
| Ureter | - | - | - | - | - | - |
| Eye | - | - | - | - | - | - |
| Brain and Other Nervous System | 1.4 | 1.8 | 0.9 | 0.7 | 30 | 1.2 |
| Endocrine System | - | - | 1.4 | - | 18 | 0.8 |
| Thyroid | - | - | 0.9 | - | 11 | 0.5 |
| Lymphomas | 4.0 | 3.6 | 5.2 | 4.2 | 99 | 4.3 |
| Hodgkin Lymphoma | - | - | - | - | 10 | 0.4 |
| Non-Hodgkin Lymphoma | 3.7 | 3.2 | 4.4 | 3.9 | 89 | 3.8 |
| Multiple Myeloma | 7.6 | 5.9 | 6.8 | 5.9 | 145 | 6.6 |
| Leukemias | 4.4 | 4.9 | 4.5 | 4.3 | 104 | 4.6 |
| Lymphocytic Leukemia | 1.2 | - | 1.1 | 0.9 | 20 | 0.9 |
| Acute Lymphocytic Leukemia | - | - | - | - | 9 | 0.4 |
| Chronic Lymphocytic Leukemia | 1.2 | - | - | - | 11 | 0.5 |
| Myeloid and Monocytic Leukemia | 1.8 | 1.7 | 2.4 | 1.9 | 45 | 2.0 |
| Acute Myeloid Leukemia | 1.7 | 1.4 | 1.4 | 1.7 | 35 | 1.5 |
| Acute Monocytic Leukemia | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - | 6 | 0.3 |
| Other Leukemia | 1.4 | 2.9 | 1.0 | 1.5 | 39 | 1.7 |
| Ill-Defined & Unspecified Sites | 15.0 | 12.6 | 16.1 | 11.4 | 309 | 13.8 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17. Age-adjusted Mortality Rates, Hispanic Males and Females
2003-2006 Combined**

| Cancer Site | Male Rate | Male Cases | Female Rate | Female Cases |
|--|-----------|------------|-------------|--------------|
| All Sites | 133.4 | 1,604 | 91.8 | 1,484 |
| Oral Cavity and Pharynx | 2.4 | 34 | 1.0 | 16 |
| Lip | - | - | - | - |
| Tongue | 0.7 | 10 | - | - |
| Salivary Gland | - | - | - | - |
| Floor of Mouth | - | - | - | - |
| Gum and Other Mouth | - | - | - | - |
| Nasopharynx | - | - | 0.3 | 5 |
| Tonsil | - | - | - | - |
| Oropharynx | 0.3 | 5 | - | - |
| Hypopharynx | - | - | - | - |
| Digestive System | 44.7 | 551 | 29.3 | 445 |
| Esophagus | 4.1 | 55 | 1.1 | 15 |
| Stomach | 8.7 | 109 | 4.8 | 77 |
| Small Intestine | 0.5 | 6 | - | - |
| Colon and Rectum | 16.2 | 186 | 10.2 | 155 |
| Colon excluding Rectum | 14.0 | 157 | 8.8 | 134 |
| Rectum and Rectosigmoid Junction | 2.2 | 29 | 1.4 | 21 |
| Anus, Anal Canal and Anorectum | - | - | - | - |
| Liver and Intrahepatic Bile Duct | 6.7 | 87 | 3.9 | 58 |
| Liver | 5.7 | 75 | 2.8 | 41 |
| Intrahepatic Bile Duct | 1.0 | 12 | 1.1 | 17 |
| Gallbladder | - | - | 1.4 | 23 |
| Pancreas | 7.8 | 96 | 6.9 | 101 |
| Respiratory System | 31.7 | 381 | 12.6 | 195 |
| Larynx | 1.7 | 22 | - | - |
| Lung and Bronchus | 29.5 | 352 | 12.3 | 190 |
| Bones and Joints | - | - | 0.2 | 5 |
| Soft Tissue (Including Heart) | 0.8 | 11 | 0.7 | 14 |
| Skin (Excluding Basal and Squamous) | 0.6 | 8 | 0.7 | 11 |
| Melanoma of the Skin | 0.3 | 5 | 0.5 | 8 |
| Breast | - | - | 14.0 | 253 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females
2003-2006 Combined**

| Cancer Site | Male Rate | Male Cases | Female Rate | Female Cases |
|--|-----------|------------|-------------|--------------|
| Female Genital System | * | * | 11.2 | 194 |
| Cervix Uteri | * | * | 2.6 | 55 |
| Corpus and Uterus, NOS | * | * | 3.5 | 55 |
| Corpus Uteri | * | * | 1.1 | 17 |
| Uterus, NOS | * | * | 2.4 | 38 |
| Ovary | * | * | 4.1 | 68 |
| Vagina | * | * | - | - |
| Vulva | * | * | 0.5 | 7 |
| Male Genital System | 16.2 | 152 | * | * |
| Prostate | 15.6 | 141 | * | * |
| Testis | - | - | * | * |
| Penis | 0.5 | 9 | * | * |
| Urinary System | 7.0 | 79 | 2.2 | 34 |
| Urinary Bladder | 3.8 | 42 | 1.2 | 18 |
| Kidney and Renal Pelvis | 2.8 | 34 | 0.9 | 14 |
| Ureter | - | - | - | - |
| Eye | - | - | - | - |
| Brain and Other Nervous System | 2.4 | 37 | 1.8 | 35 |
| Endocrine System | 0.3 | 5 | 0.4 | 8 |
| Thyroid | - | - | - | - |
| Lymphomas | 6.5 | 83 | 5.0 | 75 |
| Hodgkin Lymphoma | - | - | 0.4 | 9 |
| Non-Hodgkin Lymphoma | 6.3 | 80 | 4.5 | 66 |
| Multiple Myeloma | 2.7 | 35 | 3.0 | 44 |
| Leukemias | 4.7 | 72 | 3.0 | 53 |
| Lymphocytic Leukemia | 1.3 | 23 | 0.8 | 15 |
| Acute Lymphocytic Leukemia | 0.5 | 13 | 0.6 | 12 |
| Chronic Lymphocytic Leukemia | 0.7 | 8 | - | - |
| Myeloid and Monocytic Leukemia | 2.2 | 34 | 1.3 | 25 |
| Acute Myeloid Leukemia | 2.0 | 29 | 1.0 | 19 |
| Acute Monocytic Leukemia | - | - | - | - |
| Chronic Myeloid Leukemia | 0.2 | 5 | - | - |
| Other Leukemia | 1.1 | 15 | 0.8 | 13 |
| Ill-Defined & Unspecified Sites | 13.1 | 150 | 6.6 | 101 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 18. Comparative Mortality Rates, New Jersey and U.S., 2002-2006
 Males**

| Cancer Site | New Jersey 2002-2006 | | | United States 2002-2006 | | |
|--------------------|----------------------|-------|-------|-------------------------|-------|-------|
| | All Races Combined | White | Black | All Races Combined | White | Black |
| Population: | | | | | | |
| All Sites | 226.7 | 226.4 | 282.2 | 229.9 | 226.7 | 304.2 |
| Lung | 62.7 | 63.0 | 76.5 | 70.5 | 69.9 | 90.1 |
| Prostate | 24.5 | 22.4 | 53.4 | 25.6 | 23.6 | 56.3 |
| Colorectal | 24.1 | 24.1 | 29.9 | 21.9 | 21.4 | 31.4 |

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 19. Comparative Mortality Rates, New Jersey and U.S., 2002-2006
 Females**

| Cancer Site | New Jersey 2002-2006 | | | United States 2002-2006 | | |
|--------------------|----------------------|-------|-------|-------------------------|-------|-------|
| | All Races Combined | White | Black | All Races Combined | White | Black |
| Population: | | | | | | |
| All Sites | 166.2 | 167.3 | 188.1 | 157.8 | 157.3 | 183.7 |
| Lung | 40.1 | 41.1 | 41.5 | 40.9 | 41.9 | 40.0 |
| Breast | 27.4 | 27.3 | 33.5 | 24.5 | 23.9 | 33.0 |
| Colorectal | 17.2 | 16.9 | 22.7 | 15.4 | 14.9 | 21.6 |

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Cancer Incidence and Mortality in New Jersey, 2003-2007

Table 20. Population Denominators

| | 2002 | | | | | | 2003 | | | | | |
|-------|-----------|-----------|-----------|-----------|---------|---------|-----------|-----------|-----------|-----------|---------|---------|
| | All Races | | White | White | Black | Black | All Races | | White | White | Black | Black |
| | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| <1 | 57,574 | 55,184 | 42,061 | 40,048 | 10,609 | 10,170 | 59,387 | 56,188 | 43,158 | 40,625 | 10,853 | 10,401 |
| 01-04 | 229,215 | 218,802 | 169,716 | 161,239 | 40,826 | 39,553 | 229,688 | 219,070 | 169,190 | 160,462 | 41,166 | 39,833 |
| 05-09 | 301,810 | 287,719 | 224,714 | 213,601 | 54,425 | 52,100 | 297,426 | 283,829 | 221,388 | 210,575 | 52,955 | 50,670 |
| 10-14 | 314,281 | 299,235 | 235,701 | 223,468 | 56,991 | 55,502 | 315,426 | 300,417 | 235,955 | 223,723 | 57,150 | 55,773 |
| 15-19 | 282,336 | 265,647 | 213,212 | 199,511 | 50,089 | 48,613 | 285,817 | 269,503 | 215,759 | 202,516 | 50,705 | 49,199 |
| 20-24 | 251,818 | 238,928 | 186,050 | 174,082 | 47,139 | 46,413 | 257,883 | 242,690 | 190,203 | 177,067 | 48,587 | 47,273 |
| 25-29 | 261,761 | 257,998 | 193,505 | 184,611 | 41,831 | 46,052 | 260,709 | 254,498 | 192,927 | 182,248 | 42,064 | 45,199 |
| 30-34 | 315,091 | 317,169 | 235,581 | 231,837 | 47,789 | 53,485 | 309,129 | 310,584 | 228,785 | 224,018 | 46,961 | 53,223 |
| 35-39 | 349,085 | 357,449 | 270,046 | 272,057 | 49,742 | 56,173 | 341,510 | 349,374 | 262,252 | 264,088 | 49,009 | 54,951 |
| 40-44 | 360,268 | 368,651 | 286,778 | 287,843 | 46,976 | 53,549 | 361,567 | 369,734 | 286,123 | 287,121 | 47,608 | 54,269 |
| 45-49 | 319,516 | 332,700 | 258,893 | 264,274 | 38,178 | 45,004 | 328,987 | 341,248 | 265,562 | 269,957 | 39,649 | 46,567 |
| 50-54 | 273,091 | 292,430 | 223,613 | 233,798 | 31,288 | 39,794 | 275,189 | 294,915 | 224,680 | 235,036 | 31,447 | 40,180 |
| 55-59 | 225,717 | 245,797 | 188,211 | 201,083 | 24,142 | 30,765 | 231,559 | 251,703 | 192,115 | 204,826 | 24,930 | 31,667 |
| 60-64 | 164,389 | 185,313 | 135,217 | 150,032 | 19,094 | 25,183 | 174,251 | 195,639 | 144,156 | 158,967 | 19,428 | 25,842 |
| 65-69 | 132,071 | 157,710 | 110,777 | 130,188 | 14,598 | 20,189 | 133,926 | 159,333 | 111,594 | 130,792 | 14,912 | 20,656 |
| 70-74 | 118,495 | 154,651 | 103,571 | 133,423 | 10,941 | 15,849 | 116,578 | 151,104 | 101,148 | 129,271 | 11,035 | 16,111 |
| 75-79 | 95,611 | 141,972 | 85,790 | 126,033 | 7,334 | 12,198 | 95,416 | 140,831 | 85,223 | 124,391 | 7,504 | 12,368 |
| 80-84 | 63,059 | 109,478 | 57,569 | 99,328 | 4,086 | 7,959 | 63,825 | 110,428 | 58,045 | 99,713 | 4,222 | 8,289 |
| 85+ | 42,697 | 102,692 | 39,113 | 93,770 | 2,672 | 7,366 | 44,815 | 105,386 | 40,953 | 96,188 | 2,821 | 7,436 |
| Total | 4,157,885 | 4,389,525 | 3,260,118 | 3,420,226 | 598,750 | 665,917 | 4,183,088 | 4,406,474 | 3,269,216 | 3,421,584 | 603,006 | 669,907 |

| | 2004 | | | | | | 2005 | | | | | |
|-------|-----------|-----------|-----------|-----------|---------|---------|-----------|-----------|-----------|-----------|---------|---------|
| | All Races | | White | White | Black | Black | All Races | | White | White | Black | Black |
| | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| <1 | 59,088 | 56,635 | 42,965 | 41,361 | 10,599 | 10,101 | 56,787 | 54,149 | 41,186 | 39,218 | 10,147 | 9,764 |
| 01-04 | 231,807 | 220,935 | 169,628 | 161,031 | 41,747 | 40,208 | 232,810 | 221,577 | 169,309 | 160,939 | 42,146 | 40,243 |
| 05-09 | 293,259 | 279,578 | 218,427 | 207,087 | 51,547 | 49,402 | 288,869 | 275,944 | 215,224 | 204,187 | 49,952 | 48,324 |
| 10-14 | 313,368 | 298,434 | 233,591 | 221,876 | 56,893 | 55,059 | 308,564 | 293,181 | 229,541 | 217,613 | 55,800 | 53,486 |
| 15-19 | 291,475 | 275,248 | 219,903 | 206,556 | 51,768 | 50,527 | 297,784 | 281,067 | 223,998 | 210,419 | 53,329 | 51,956 |
| 20-24 | 263,181 | 249,532 | 194,966 | 183,715 | 49,176 | 47,108 | 268,293 | 253,667 | 199,760 | 188,163 | 49,482 | 46,788 |
| 25-29 | 258,705 | 247,930 | 190,484 | 176,450 | 42,940 | 45,381 | 257,703 | 246,814 | 188,536 | 175,387 | 43,986 | 45,611 |
| 30-34 | 301,935 | 302,578 | 221,189 | 216,171 | 46,076 | 51,980 | 292,118 | 290,688 | 212,541 | 205,574 | 44,652 | 49,903 |
| 35-39 | 333,131 | 339,793 | 253,985 | 254,547 | 47,773 | 53,872 | 328,319 | 333,297 | 248,014 | 247,392 | 47,183 | 53,349 |
| 40-44 | 363,170 | 370,437 | 285,446 | 285,616 | 48,405 | 55,267 | 360,851 | 367,309 | 282,077 | 281,749 | 48,610 | 55,061 |
| 45-49 | 336,321 | 349,048 | 270,522 | 275,246 | 40,761 | 47,805 | 342,648 | 354,983 | 273,640 | 278,528 | 42,564 | 49,521 |
| 50-54 | 282,236 | 299,240 | 229,978 | 238,248 | 32,440 | 40,490 | 289,606 | 304,605 | 236,312 | 242,603 | 32,795 | 40,527 |
| 55-59 | 239,439 | 260,684 | 198,105 | 211,224 | 25,765 | 33,064 | 249,012 | 271,123 | 205,059 | 218,518 | 27,093 | 34,880 |
| 60-64 | 178,970 | 201,966 | 148,240 | 164,113 | 19,484 | 26,243 | 183,275 | 205,732 | 151,953 | 167,191 | 19,610 | 26,128 |
| 65-69 | 136,934 | 161,097 | 113,549 | 131,726 | 15,280 | 20,981 | 138,698 | 162,872 | 114,464 | 132,455 | 15,421 | 21,496 |
| 70-74 | 113,862 | 147,757 | 97,958 | 125,141 | 11,120 | 16,482 | 111,936 | 144,819 | 95,604 | 121,518 | 11,202 | 16,701 |
| 75-79 | 94,713 | 137,900 | 84,254 | 121,133 | 7,535 | 12,378 | 94,174 | 135,565 | 83,234 | 118,393 | 7,738 | 12,524 |
| 80-84 | 65,146 | 112,452 | 59,099 | 101,219 | 4,352 | 8,650 | 65,168 | 112,074 | 58,823 | 100,465 | 4,505 | 8,776 |
| 85+ | 45,993 | 106,793 | 41,797 | 97,228 | 3,015 | 7,600 | 48,226 | 110,350 | 43,683 | 100,099 | 3,204 | 8,012 |
| Total | 4,202,733 | 4,418,037 | 3,274,086 | 3,419,688 | 606,676 | 672,598 | 4,214,841 | 4,419,816 | 3,272,958 | 3,410,411 | 609,419 | 673,050 |

| | 2006 | | | | | | 2007 | | | | | |
|-------|-----------|-----------|-----------|-----------|---------|---------|-----------|-----------|-----------|-----------|---------|---------|
| | All Races | | White | White | Black | Black | All Races | | White | White | Black | Black |
| | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| <1 | 55,610 | 52,714 | 39,822 | 37,659 | 10,375 | 9,929 | 57,210 | 54,436 | 40,461 | 38,531 | 11,206 | 10,648 |
| 01-04 | 230,927 | 220,239 | 168,010 | 160,179 | 41,283 | 39,236 | 228,288 | 217,027 | 165,298 | 157,200 | 40,911 | 38,955 |
| 05-09 | 285,400 | 272,058 | 211,287 | 200,020 | 49,684 | 48,315 | 283,659 | 270,658 | 209,031 | 198,291 | 49,737 | 47,985 |
| 10-14 | 303,404 | 288,673 | 225,400 | 213,977 | 54,264 | 51,851 | 298,067 | 283,750 | 221,479 | 210,023 | 52,479 | 50,193 |
| 15-19 | 301,306 | 284,496 | 226,397 | 212,418 | 54,033 | 52,818 | 303,552 | 286,062 | 227,462 | 213,183 | 54,576 | 53,174 |
| 20-24 | 273,696 | 259,623 | 205,110 | 194,171 | 49,602 | 46,950 | 274,707 | 262,168 | 205,904 | 196,151 | 49,945 | 47,648 |
| 25-29 | 257,220 | 245,181 | 186,970 | 173,442 | 45,747 | 46,250 | 261,751 | 247,130 | 190,072 | 175,854 | 46,346 | 45,820 |
| 30-34 | 282,305 | 279,032 | 204,678 | 195,922 | 42,789 | 47,977 | 276,980 | 273,033 | 200,404 | 190,564 | 42,272 | 47,402 |
| 35-39 | 323,983 | 328,582 | 242,340 | 241,691 | 46,985 | 52,720 | 319,590 | 321,402 | 236,453 | 233,488 | 46,600 | 52,179 |
| 40-44 | 355,076 | 361,437 | 275,522 | 275,088 | 48,146 | 54,981 | 346,242 | 354,405 | 266,939 | 268,080 | 47,249 | 54,155 |
| 45-49 | 348,053 | 359,436 | 277,079 | 281,261 | 43,706 | 50,456 | 350,810 | 360,411 | 278,258 | 280,659 | 44,509 | 51,246 |
| 50-54 | 297,499 | 311,287 | 241,806 | 247,139 | 33,945 | 41,382 | 307,276 | 320,189 | 248,780 | 253,599 | 35,422 | 42,466 |
| 55-59 | 257,794 | 279,396 | 211,980 | 224,434 | 28,076 | 36,405 | 254,720 | 274,327 | 207,960 | 218,798 | 28,259 | 36,479 |
| 60-64 | 187,719 | 210,959 | 155,566 | 171,554 | 19,655 | 26,067 | 202,914 | 227,135 | 169,120 | 185,273 | 20,544 | 27,459 |
| 65-69 | 140,093 | 165,291 | 115,352 | 133,981 | 15,528 | 21,761 | 144,255 | 170,224 | 118,750 | 137,902 | 15,632 | 22,103 |
| 70-74 | 111,702 | 142,773 | 94,437 | 118,569 | 11,512 | 17,238 | 111,191 | 141,315 | 93,510 | 116,765 | 11,471 | 17,242 |
| 75-79 | 93,115 | 133,507 | 82,075 | 116,031 | 7,620 | 12,557 | 91,598 | 130,804 | 80,060 | 112,739 | 7,853 | 12,862 |
| 80-84 | 65,052 | 110,696 | 58,430 | 98,599 | 4,628 | 9,010 | 65,227 | 109,894 | 58,476 | 97,512 | 4,651 | 9,122 |
| 85+ | 50,634 | 114,250 | 45,747 | 103,610 | 3,387 | 8,172 | 52,960 | 117,759 | 47,711 | 106,477 | 3,569 | 8,521 |
| Total | 4,220,588 | 4,419,630 | 3,268,008 | 3,399,745 | 610,965 | 674,075 | 4,230,997 | 4,422,129 | 3,266,128 | 3,391,089 | 613,231 | 675,659 |

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

Cancer Incidence and Mortality in New Jersey, 2003-2007

Table 20 (continued). Population Denominators

Hispanic Population, 2003-2007

| | Male Total | Male 2003 | Male 2004 | Male 2005 | Male 2006 | Male 2007 | Female Total | Female 2003 | Female 2004 | Female 2005 | Female 2006 | Female 2007 |
|-------|---------------|--------------|--------------|--------------|--------------|--------------|-----------------|----------------|----------------|----------------|----------------|----------------|
| <1 | 71,511 | 13,683 | 14,132 | 13,935 | 14,177 | 15,584 | 68,376 | 12,891 | 13,747 | 13,428 | 13,536 | 14,774 |
| 00-04 | 256,815 | 46,301 | 49,775 | 52,271 | 53,567 | 54,901 | 244,917 | 43,999 | 47,100 | 49,832 | 51,351 | 52,635 |
| 05-09 | 266,737 | 51,494 | 51,677 | 52,597 | 54,387 | 56,582 | 253,736 | 49,059 | 49,398 | 50,149 | 51,510 | 53,620 |
| 10-14 | 259,795 | 51,025 | 51,985 | 52,198 | 52,351 | 52,236 | 247,263 | 48,964 | 49,567 | 49,368 | 49,813 | 49,551 |
| 15-19 | 247,382 | 47,036 | 47,743 | 49,512 | 50,857 | 52,234 | 236,548 | 44,604 | 45,684 | 47,518 | 48,750 | 49,992 |
| 20-24 | 286,329 | 59,478 | 58,675 | 57,143 | 56,029 | 55,004 | 248,497 | 49,627 | 49,951 | 49,819 | 49,389 | 49,711 |
| 25-29 | 323,839 | 62,769 | 63,974 | 65,120 | 65,879 | 66,097 | 264,342 | 52,450 | 52,225 | 52,755 | 53,368 | 53,544 |
| 30-34 | 316,621 | 60,994 | 62,486 | 63,301 | 64,282 | 65,558 | 279,998 | 55,017 | 56,208 | 56,247 | 56,223 | 56,303 |
| 35-39 | 298,268 | 57,754 | 58,433 | 59,638 | 60,639 | 61,804 | 276,859 | 54,421 | 54,518 | 55,279 | 56,019 | 56,622 |
| 40-44 | 271,432 | 50,241 | 52,838 | 54,691 | 56,345 | 57,317 | 259,165 | 48,939 | 50,753 | 51,947 | 53,250 | 54,276 |
| 45-49 | 213,557 | 38,165 | 40,173 | 42,717 | 45,039 | 47,463 | 215,557 | 39,180 | 41,262 | 43,367 | 45,080 | 46,668 |
| 50-54 | 158,641 | 28,335 | 29,912 | 31,433 | 33,453 | 35,508 | 167,132 | 30,393 | 31,827 | 33,177 | 34,817 | 36,918 |
| 55-59 | 120,793 | 21,624 | 22,973 | 24,386 | 25,408 | 26,402 | 134,006 | 24,266 | 25,546 | 27,222 | 28,126 | 28,846 |
| 60-64 | 85,530 | 15,787 | 16,122 | 16,872 | 17,714 | 19,035 | 100,575 | 18,333 | 19,163 | 19,746 | 21,042 | 22,291 |
| 65-69 | 63,857 | 11,464 | 12,309 | 12,930 | 13,392 | 13,762 | 77,226 | 14,143 | 14,785 | 15,470 | 16,113 | 16,715 |
| 70-74 | 43,658 | 7,871 | 8,216 | 8,745 | 9,203 | 9,623 | 58,239 | 10,600 | 11,099 | 11,703 | 12,088 | 12,749 |
| 75-79 | 28,765 | 4,988 | 5,393 | 5,778 | 6,178 | 6,428 | 41,803 | 7,400 | 7,955 | 8,331 | 8,850 | 9,267 |
| 80-84 | 16,364 | 2,725 | 2,998 | 3,245 | 3,556 | 3,840 | 26,781 | 4,723 | 5,025 | 5,401 | 5,629 | 6,003 |
| 85+ | 11,919 | 1,918 | 2,105 | 2,347 | 2,612 | 2,937 | 25,204 | 4,218 | 4,600 | 4,982 | 5,453 | 5,951 |
| Total | 3,341,813 | 633,652 | 651,919 | 668,859 | 685,068 | 702,315 | 3,226,224 | 613,227 | 630,413 | 645,741 | 660,407 | 676,436 |

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

**Table 21. Age Distribution (%) of Incidence Cases in New Jersey, 2003-2007
All Races, Both Sexes**

| Cancer Site | 0-19 | 20-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75-84 | 85+ | All Ages | Cases |
|----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|----------|---------|
| All Sites | 0.9% | 2.4% | 5.7% | 13.4% | 21.9% | 24.6% | 23.3% | 8.0% | 100% | 231,824 |
| Male | 1.0% | 1.9% | 3.7% | 11.4% | 23.8% | 28.1% | 23.8% | 6.4% | 100% | 117,453 |
| Female | 0.8% | 2.8% | 7.6% | 15.6% | 19.9% | 21.0% | 22.7% | 9.5% | 100% | 114,371 |
| Oral Cavity and Pharynx | 0.5% | 1.9% | 6.3% | 20.2% | 26.0% | 22.3% | 16.5% | 6.2% | 100% | 4,619 |
| Esophagus | 0.0% | 0.5% | 2.2% | 11.9% | 24.6% | 27.0% | 26.0% | 7.9% | 100% | 2,330 |
| Stomach | 0.2% | 1.4% | 4.5% | 10.3% | 17.8% | 23.8% | 29.2% | 12.9% | 100% | 4,106 |
| Colon and Rectum | 0.0% | 0.9% | 3.5% | 10.7% | 17.8% | 23.5% | 30.0% | 13.7% | 100% | 24,696 |
| Male | 0.1% | 0.8% | 3.8% | 11.5% | 20.5% | 26.1% | 28.0% | 9.3% | 100% | 12,273 |
| Female | 0.0% | 1.0% | 3.2% | 9.9% | 15.0% | 20.8% | 31.9% | 18.1% | 100% | 12,423 |
| Colon excluding Rectum | 0.0% | 0.8% | 3.0% | 9.2% | 16.3% | 23.3% | 31.9% | 15.5% | 100% | 17,769 |
| Rectum | 0.0% | 1.0% | 4.8% | 14.6% | 21.6% | 24.0% | 24.9% | 9.0% | 100% | 6,927 |
| Liver and Intrahepatic Bile Duct | 0.7% | 0.9% | 2.9% | 17.3% | 25.2% | 23.0% | 23.1% | 6.8% | 100% | 2,906 |
| Pancreas | 0.1% | 0.4% | 2.2% | 8.8% | 19.2% | 24.6% | 31.4% | 13.4% | 100% | 5,838 |
| Lung and Bronchus | 0.0% | 0.3% | 1.8% | 8.6% | 21.0% | 30.2% | 30.3% | 8.0% | 100% | 29,996 |
| Male | 0.0% | 0.2% | 1.5% | 8.5% | 21.8% | 31.0% | 30.0% | 6.9% | 100% | 15,294 |
| Female | 0.0% | 0.3% | 2.1% | 8.6% | 20.1% | 29.3% | 30.5% | 9.1% | 100% | 14,702 |
| Bones and Joints | 27.4% | 15.6% | 12.6% | 13.9% | 9.9% | 7.7% | 8.6% | 4.3% | 100% | 467 |
| Soft Tissue including Heart | 6.4% | 9.7% | 13.0% | 15.1% | 15.2% | 16.1% | 17.6% | 7.0% | 100% | 1,521 |
| Melanoma of the Skin | 0.8% | 6.1% | 11.4% | 17.0% | 18.9% | 20.0% | 19.1% | 6.7% | 100% | 9,605 |
| Breast | 0.0% | 1.8% | 10.9% | 22.2% | 22.8% | 19.3% | 17.1% | 5.9% | 100% | 32,495 |
| Cervix Uteri | 0.1% | 11.8% | 24.0% | 25.6% | 16.6% | 12.2% | 7.5% | 2.2% | 100% | 2,196 |
| Corpus and Uterus, NOS | 0.0% | 0.9% | 4.6% | 17.5% | 32.1% | 23.6% | 16.3% | 4.8% | 100% | 7,427 |
| Ovary | 1.1% | 2.9% | 7.4% | 19.8% | 23.0% | 18.8% | 18.5% | 8.5% | 100% | 3,606 |
| Prostate | 0.0% | 0.0% | 0.7% | 9.1% | 30.2% | 35.1% | 20.9% | 4.0% | 100% | 34,856 |
| Testis | 5.2% | 43.9% | 28.4% | 16.1% | 4.3% | 1.4% | 0.8% | 0.0% | 100% | 1,192 |
| Urinary Bladder | 0.1% | 0.4% | 1.8% | 7.1% | 18.3% | 27.3% | 32.8% | 12.2% | 100% | 12,214 |
| Kidney and Renal Pelvis | 1.2% | 1.6% | 6.0% | 15.4% | 24.2% | 25.0% | 21.2% | 5.5% | 100% | 7,024 |
| Brain and Other Nervous System | 12.1% | 7.0% | 9.2% | 16.0% | 17.3% | 18.1% | 15.4% | 5.0% | 100% | 3,235 |
| Thyroid | 1.6% | 14.6% | 21.7% | 24.6% | 18.0% | 11.2% | 6.8% | 1.4% | 100% | 6,095 |
| Hodgkin Lymphoma | 11.0% | 29.7% | 16.0% | 13.3% | 10.4% | 9.6% | 7.9% | 2.2% | 100% | 1,449 |
| Non-Hodgkin Lymphoma | 1.5% | 3.8% | 7.2% | 13.6% | 18.7% | 21.4% | 24.9% | 8.9% | 100% | 9,705 |
| Myeloma | 0.0% | 0.6% | 3.4% | 12.2% | 20.5% | 26.2% | 28.2% | 9.0% | 100% | 2,893 |
| Leukemia | 9.2% | 3.8% | 5.1% | 10.5% | 16.2% | 19.8% | 25.1% | 10.3% | 100% | 6,039 |
| Acute Lymphocytic Leukemia | 59.5% | 7.8% | 4.6% | 6.2% | 7.7% | 7.4% | 5.2% | 1.7% | 100% | 716 |
| Chronic Lymphocytic Leukemia | 0.1% | 0.2% | 1.8% | 10.0% | 19.1% | 25.2% | 30.8% | 12.9% | 100% | 2,129 |
| Acute Myeloid Leukemia | 4.4% | 5.2% | 6.5% | 11.2% | 16.1% | 20.3% | 26.6% | 9.7% | 100% | 1,758 |
| Chronic Myeloid Leukemia | 2.4% | 6.9% | 9.1% | 13.7% | 19.0% | 17.4% | 23.6% | 8.1% | 100% | 696 |
| Other Leukemia | 4.4% | 5.1% | 4.1% | 7.6% | 9.2% | 19.0% | 30.1% | 20.6% | 100% | 316 |
| Mesothelioma | 0.0% | 0.1% | 1.6% | 4.7% | 12.6% | 26.3% | 41.5% | 13.3% | 100% | 701 |
| Kaposi Sarcoma | 0.0% | 10.8% | 24.7% | 15.1% | 13.6% | 8.0% | 16.7% | 11.2% | 100% | 251 |

**Table 22. Median Age of Cancer Patients at Diagnosis, New Jersey 2003-2007
By Primary Cancer Site, Race and Sex**

| Cancer Site | All Races | | | Whites | | | Blacks | | |
|----------------------------------|-----------|------|--------|--------|------|--------|--------|------|--------|
| | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| All Sites | 67 | 68 | 66 | 68 | 68 | 67 | 63 | 64 | 62 |
| Oral Cavity and Pharynx | 62 | 61 | 66 | 63 | 61 | 68 | 59 | 60 | 56 |
| Esophagus | 69 | 67 | 73 | 69 | 68 | 75 | 63 | 63 | 64 |
| Stomach | 72 | 69 | 75 | 73 | 70 | 76 | 69 | 67 | 72 |
| Colon and Rectum | 72 | 70 | 75 | 73 | 71 | 76 | 67 | 66 | 68 |
| Colon excluding Rectum | 74 | 72 | 76 | 75 | 72 | 77 | 68 | 67 | 68 |
| Rectum and Rectosigmoid Junction | 68 | 66 | 70 | 69 | 67 | 72 | 64 | 64 | 64 |
| Liver and Intrahepatic Bile Duct | 66 | 63 | 73 | 68 | 65 | 75 | 60 | 58 | 64 |
| Pancreas | 73 | 70 | 75 | 73 | 71 | 76 | 69 | 66 | 72 |
| Lung and Bronchus | 71 | 71 | 71 | 72 | 71 | 72 | 66 | 66 | 67 |
| Bones and Joints | 39 | 39 | 40 | 41 | 41 | 44 | 39 | 36 | 41 |
| Soft Tissue including Heart | 59 | 59 | 59 | 61 | 61 | 62 | 46 | 45 | 47 |
| Melanoma of the Skin | 62 | 65 | 58 | 62 | 65 | 58 | 69 | 71 | 65 |
| Breast | 61 | 70 | 61 | 62 | 71 | 62 | 58 | 65 | 58 |
| Cervix Uteri | * | * | 49 | * | * | 50 | * | * | 50 |
| Corpus and Uterus, NOS | * | * | 63 | * | * | 63 | * | * | 64 |
| Ovary | * | * | 62 | * | * | 63 | * | * | 62 |
| Prostate | * | 67 | * | * | 68 | * | * | 65 | * |
| Testis | * | 35 | * | 35 | 35 | * | 35 | 35 | * |
| Urinary Bladder | 73 | 73 | 74 | 73 | 73 | 74 | 70 | 68 | 72 |
| Kidney and Renal Pelvis | 65 | 64 | 67 | 66 | 65 | 68 | 62 | 61 | 63 |
| Brain and Other Nervous System | 58 | 57 | 60 | 59 | 58 | 61 | 50 | 50 | 50 |
| Thyroid | 49 | 53 | 48 | 49 | 53 | 48 | 51 | 57 | 50 |
| Hodgkin Lymphoma | 41 | 41 | 40 | 42 | 42 | 41 | 39 | 39 | 40 |
| Non-Hodgkin Lymphoma | 67 | 65 | 69 | 68 | 66 | 71 | 55 | 53 | 59 |
| Myeloma | 70 | 69 | 71 | 71 | 70 | 72 | 67 | 66 | 69 |
| Leukemia | 67 | 66 | 70 | 69 | 67 | 71 | 60 | 59 | 61 |
| Acute Lymphocytic Leukemia | 13 | 12 | 13 | 14 | 14 | 14 | 11 | 10 | 15 |
| Chronic Lymphocytic Leukemia | 72 | 70 | 75 | 73 | 71 | 76 | 67 | 64 | 69 |
| Acute Myeloid Leukemia | 68 | 68 | 69 | 70 | 69 | 70 | 60 | 58 | 61 |
| Chronic Myeloid Leukemia | 64 | 65 | 63 | 66 | 66 | 67 | 59 | 60 | 56 |
| Other Leukemia | 75 | 73 | 77 | 77 | 75 | 79 | 68 | 61 | 71 |
| Mesothelioma | 76 | 76 | 76 | 76 | 76 | 76 | 73 | 75 | 70 |
| Kaposi Sarcoma | 53 | 50 | 81 | 64 | 59 | 82 | 41 | 41 | 43 |

* Non-applicable gender.